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1.1. NOVEL DRUG DELIVERY SYSTEM (Bankar G.S and Rhodes C.T., 
2009; Brahmankar D.M and Jaiswal S.B., 2005; Chein Y.W., 2002) 
The goal of a sustained release dosage form is to maintain therapeutic blood or 
tissue levels of the drug for an extended and specified period of time. This is generally 
accomplished by attempting to obtain "zero-order" release from the dosage form. 
Zero-order release constitutes drug release from the dosage form which is 
independent of the amount of drug in the delivery system (i.e. a constant release rate). 
Sustained-release systems generally do not attain this type of release and usually try 
to mimic zero-order release by providing drug in a slow first-order fashion   (i.e., 
concentration release dependent). Systems that are designated as prolonged release 
can also be considered as attempts at achieving sustained-release delivery. 
The term “Controlled- release drug product” has been used to describe various 
types of oral extended release rate dosage forms, including sustained release (SR), 
sustained action, prolonged action, long action and retarded release. These terms for 
extended release dosage forms were introduced by drug companies to reflect a special 
design for producing an extended release (ER) dosage form or used as a marketing 
term. 
In the last two-three decades interest in sustained release drug delivery 
systems is remarkably increasing. This has been due to various factors viz. 
 Developing new drug entities. 
 Expiration of international patents 
 Discovery of new polymeric materials suitable for prolonging the drug release. 
1. INTRODUCTION 
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 Need of therapeutic efficacy and safety achieved by sustained release drug 
delivery. 
The subject of sustain release has been reviewed by various authors. Several 
books have been published on it. These reviews and books provide not only the 
mechanisms and technology of production of dosage forms but also the information 
on clinical evidence and performance. 
There are many definitions of sustained release but the simplest definition is 
“Any drug or dosage form or medication that prolongs the therapeutic activity of 
drug’’. The overall objective is that, once the drug-carrier material has been injected 
or otherwise implanted or taken orally into the body, the drug is released at a 
predetermined rate for some desired period of time. Controlled release technology is 
relatively new field and as a consequence, research in this field has been extremely 
fertile and has produced many discoveries. 
Non-immediate release delivery systems may be divided conveniently into 4 
categories, 
A. Delayed release 
B. Sustained release 
a) Controlled release 
b) Prolonged release 
C.   Site- specific release 
D.   Receptor release 
Delayed – release systems are those that use repetitive, intermittence dosing 
of a drug from one or more immediate release units incorporated into a single dosage 
forms to make delayed action. Example: Repeat- action tablets and capsules, enteric 
coated tablets where timed release achieved by a barrier coating. 
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Sustained- release systems includes any drug delivery system that achieves 
slow release of drug over an extended period of time. 
Controlled release systems are those systems which are successful 
maintaining constant drug levels in blood or target release (i.e.) release rate of drug 
occurs in controlled manner. 
Prolonged released systems only extends the duration of action and drug 
release that achieved by conventional drug delivery. 
Site specific and receptor release refers to targeting of drug directly to a 
certain biological location. In the case of site- specific release, the target is a certain 
organ or tissue, for receptor release, the target is the particular receptor for a drug 
within an organ or tissue. 
 
 
 
Figure 1.1: A hypothetical plasma concentration vs time profile from conventional  
 
                   multiple and single doses of sustained release drug delivery formulations. 
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Control release system differs from Sustain release system which simply 
prolongs the drug release and hence plasma drug levels for an extended period of time 
(i.e. not necessarily at a predetermined rate). Thus the chief objective of most products 
should be controlled delivery to reduce dosing frequency to an extent that once daily 
dose is sufficient for therapeutic management through a uniform plasma concentration 
at steady state. 
 Advantages of sustained release drug delivery system (Bankar G.S and Rhodes 
C.T., 2009; Chein Y.W., 2002) 
Some advantages are as follows 
1. Reduction in dosing frequency. 
2. Reduced fluctuation in circulating drug levels. 
3. Increased patient convenience and compliance. 
4. Avoidance of night time dosing. 
5. More uniform effect. 
6. Maximum utilization of drug. 
7. Reduction in GI irritation and other side effects. 
8. Reduction in health care cost through improved therapy. 
9. Improve bioavailability of some drugs. 
Disadvantages of sustained drug delivery system  
1. Decreased systemic availability in comparison to immediate release 
conventional dosage form. This may be due to 
 Incomplete release, 
 Increased first-pass metabolism, Increased instability, 
 Insufficient residence time for complete release, 
 Site specific absorption, pH dependant solubility, etc. 
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2. Poor in vitro-in vivo correlation. 
3. Possibility of dose dumping. 
4. Retrieval of drug is difficult in case of toxicity, poisoning, or 
hypersensitivity reactions. 
5. Higher cost of formulation. 
 
PREREQUISITES FOR A DRUG TO BE SUITABLE FOR DESIGN OF ORAL 
SUSTAINED RELEASE DOSAGE FORM    (Bandyopadhyay A .K., 2008) 
Some characteristics make a drug more suitable for extended release dosing, such as 
1. Elimination half-life between 2 to 8 hours. 
2. Broader therapeutic index. 
3. Moderate unit dose. 
4. Significant extent of absorption in GIT. 
5. Optimum solubility characteristics. 
6. Minimal first-pass clearance. 
FACTORS INFLUENCING THE DESIGN AND PERFORMANCE OF ORAL 
SUSTAINED RELEASE PRODUCTS                                         
Oral drug delivery is the most widely utilized route of administration among 
all the routes that have been explored for the systemic delivery of drugs via various 
pharmaceutical products in different dosage forms. Irrespective of their mode of 
delivery (immediate, sustained or controlled release) and the design of dosage forms 
(either solid or liquid) they must be developed within the intrinsic characteristics of 
GIT physiology. Therefore a fundamental understanding of pharmacokinetics, 
pharmacodynamics and formulation design is essential to achieve a systematic 
approach to the successful development of an oral pharmaceutical dosage form. A 
number of variables such as drug properties, route of delivery, target sites, duration of 
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therapy, the disease state and patient variables must be considered. The formulation 
and performance of sustained release products are greatly influenced by the 
physicochemical and biological properties of drug. 
1.2. DRUG PROPERTIES RELEVANT TO SUSTAINED RELEASE 
FORMULATIONS                                                                                                                                             
(Bankar G.S and Rhodes C.T., 2009; Robinson J.R and Lee V.H.L., 2005) 
During design of sustained release delivery systems, variables such as the 
route of drug delivery, the type of delivery system, the disease being treated, the 
patient, the length of therapy and the properties of the drug, are considered of 
particular interest to the scientist designing the system are the constraints imposed by 
the properties of the drug. These properties are classified as, 
A) Physicochemical properties  
B) Biological properties 
These properties have the greatest effect on the behavior of the drug in the 
delivery system and in the body. There is no clear-cut distinction between these two 
categories since the biological properties of a drug are a function of its 
physicochemical properties. By definition, physicochemical properties are those that 
can be determined from in vitro experiments and biological properties will be those 
that result from typical pharmacokinetic studies of the absorption, distribution, 
metabolism, and excretion (ADME) characteristics of a drug and those resulting from 
pharmacological studies. 
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A) Physicochemical Properties 
a) Dose Size 
b) Aqueous Solubility and pKa 
c) Partition Coefficient 
d) Drug Stability 
e) Molecular Size and Diffusivity 
f) Drug Protein Binding 
B) Biological Properties 
a) Absorption 
b) Distribution 
c) Metabolism 
d) Elimination and Biological Half-Life 
e) Margin of Safety (Toxicity). 
 
A. Physiochemical properties 
a) Dose size: For orally administered drugs, there is an upper limit to the bulk size 
of the dose to be administered. In general, a single dose of 0.5 – 11.0 gm for 
conventional dosage form is considered maximal. 
b) Aqueous Solubility: Extremes in aqueous solubility are under desirable in the 
preparation of a SR product. For drug with low water solubility, it will be difficult 
to incorporate into a SR formulation. The lower limit of solubility for such 
product has been reported to be 0.1 mg/ml. 
c) Partition Co-efficient: Drug that are very lipid soluble or water soluble i.e. 
extremes in partition co-efficient, will demonstrate either low flux in to the tissues 
or rapid flux followed by accumulation in the tissues. Both extremes are 
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undesirable for a SR system Eg: Phenothiazines class of compounds is highly lipid 
soluble. 
d) Drug Stability : since most oral SR systems, by necessity are designed to release 
their contents over much of the length of the GIT, drugs which are unstable in the 
environment of the intestine might be difficult to formulate into prolonged release 
systems. 
Eg: Propanthdine and Probanthine. 
B. Biological properties 
         a)  Absorption:  Drugs that are slowly absorbed or absorbed with variable 
absorption rate are poor candidates for SR systems. For oral dosage forms the 
lower limit on the absorption rate constant  in the range of 0.17 to 0.23 hr -
1(assuming GI transit time of 8-12 hr -1). 
b) Metabolism: Drugs that are significantly metabolized, especially in region of 
small intestine, can show decreased bioavailability from SR dosage forms, 
because less total drug is presented to enzymatic process during a specific period. 
This allows more complete conversion of drug to its metabolite. 
c) Therapeutic Index:  Drugs with a narrow therapeutic range which require 
precise control over the blood levels of the drug are unsuitable for SR dosage 
forms. 
d) Half Life: The biological half life and duration of action of drug obviously 
plays a major role in considering a drug for SR systems. Drugs with a very short 
half life (>2 hours) require large amounts of drug to maintain sustained effects 
and drugs with longer life (<8hours) because their effects are already sustained. 
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1.3. PRINCIPLE BEHIND SR/CR DRUG RELEASE (Bankar G.S and Rhodes 
C.T., 2009; Brahmankar D.M and Jaiswal S.B., 2009; Robinson J.R and Lee V.H.L., 
2005) 
Dissolution and diffusion controlled systems have classically been of primary 
importance in oral delivery of medication because of their relative ease of production 
and cost compared with other methods of sustained or controlled delivery. Most of 
these systems are solids, although a few liquids and suspension have been recently 
introduced. 
The classification of such systems is as follows: 
1. Diffusion controlled systems. 
2. Dissolution controlled systems. 
3. Dissolution and Diffusion controlled systems. 
4. Osmotically controlled systems. 
5. Ion exchange systems. 
 
1. Diffusion Controlled  Systems 
Diffusion systems are characterized by the release rate being dependent on its 
diffusion through an inert membrane barrier. Usually this barrier is an insoluble 
polymer. In general two types of sub classes of diffusion systems are recognized they 
are 
a. Reservoir devices. 
b. Matrix devices. 
a. Reservoir devices 
Reservoir devices are characterized by a core drug reservoir surrounded by a 
polymeric membrane. 
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Figure 1.2: Systematic representation of diffusion controlled drug release matrix 
system. 
Figure 1.2 Schematic representation of reservoir diffusion device Cm (o), and 
Cm (d) represent concentration of drug inside surfaces of membrane and C (o) & C 
(d) represents concentration in adjacent regions. 
If it is assumed that the drug on the both side of membrane is in equilibrium 
with its respective membrane surface which in equilibrium between the membrane 
surfaces and their bathing solutions as shown in Figure 1.2 
Therefore the concentration just inside the membrane surface can be related to 
the concentration in the adjacent region by following expression. 
K = Cm (o) /C(d)      at  X = o                                   (2) 
K = Cm (d) / C(d)     at  X = d                                   (3) 
Where K = partition coefficient. If we consider K & D are constants 
then equation (1) becomes, 
J = D K C/d                                                (4) 
 Where c is the concentration difference across the membrane and d 
is path length of diffusion. The simplest system to consider is that of slab, where drug 
release is from only one surface as shown Figure 1.2  in this case equation (4) 
becomes 
            dMt/ dt  =    ADK C/ d                                     (5) 
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The process of diffusion is generally described by Ficks equation, 
                   J         =     -D dc/dx 
Where,  J         -- Flux (amount/ area –time) 
D     -- Diffusion co-efficient of drug in the membrane (area / time)   
Dc/dx  -- rate of exchange in concentration C, with respect to a 
distance X         in the membrane. 
Advantages 
1. Zero order delivery is possible. 
2. Release rate variable with polymer type. 
Disadvantages 
1. Potential toxicity if system fails. 
2. System must be physically removed from implant sites. 
3. Difficult to deliver high molecular weight compounds. 
4. Generally increased cost per dosage units. 
b. Matrix Devices 
It contains of drug dispersed homogeneously throughout a polymer matrix. In 
this model, drug in the outside layer exposed to bath solution is dissolved first and 
then diffuses out of the matrix. The following equation describe the rate of release of 
drug dispersed in an inert matrix system have been derived by Higuchi. 
                         Dm/dh  = Codh – Cs/2. 
Where,   dm      = Change in the amount of drug released per unit area. 
                         dh      = Change in the thickness of the zone of matrix that have 
been depleted of drug. 
                    Co      =  Total amount of drug in unit volume of matrix. 
                    Cs      = Saturated concentration of drug within the matrix. 
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              Figure 1.3: Release of drug dispersed in an inert matrix system. 
Advantages 
1. Can deliver high molecular weight compounds. 
2. Easier to produce than reservoir devices. 
Disadvantages 
1. Removal of remaining matrix is necessary for implanted systems. 
2. Cannot obtain zero order release. 
Diffusion Rate Modifications 
Modification of the following will change the rate of diffusion 
(a) Thickness of the separating layer 
(b) Porosity 
(c) Partition coefficient 
(d) Modification of the diffusion co-efficient. 
(e) Modification of efficient molecular size. 
(f) Modification of viscosity. 
(g) Modification of concentration. 
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2. Dissolution-controlled Systems 
Drug with a slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This 
includes preparing appropriate salts or derivatives, coating the drug with a slowly 
dissolving material, or incorporating it into a tablet with a slowly dissolving carrier. 
The dissolution process at steady state, is described by Noyes-Whitney 
equation, 
dc/dt = KDA(Cs-C) = D/h A(Cs-C) 
Where, 
dc/dt  = Dissolution rate. 
KD = Diffusion co-efficient 
A         = surface area of the dissolving solid 
Cs = Saturation solubility of the solid. 
C = Concentration of solute in bulk solution. 
H = Thickness of diffusion layer. 
Principles of dissolution rate modification 
The following are may affect dissolution rate modification of 
(a) Solubility, 
(b) Specific area, 
(c) Particle shape and surface structure, 
(d) Dissolution conditions (contact of solid particles with the 
Solvent) and 
(e) Crystallographic modification. 
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3. Dissolution and Diffusion - Controlled release system 
Normally, therapeutic systems will never be dependent on dissolution only or 
diffusion only. In practice, the dominant mechanism for release will over shadow 
other processes enough to allow classification as either dissolution rate limited or 
diffusion controlled. 
The mechanism of release from simple erodible slabs, cylinders and spheres 
has been described by Hopenberg are described as 
   Mt/M = 1 - (1- Kot/Co a)n 
Where,   n = 2 for cylinder and 
n = 1 for a slab. 
a = Radius of sphere or cylinder or half height of a slab. 
Mt  = Mass of drug release at time t 
M = Mass released infinite time. 
Advantages 
1. Easier to produce than reservoir devices. 
2. Can deliver high molecular weight compounds. 
3. Removal from implant sites is not necessary. 
Disadvantages 
1. Difficult to control kinetics owning to multiple process of release. 
2. Potential toxicity of degraded polymer must be considered. 
4. Osmotically controlled systems 
This device is fabricated as tablet that contains water soluble osmotically active 
drug, of that was blended with osmotically active diluents by coating the tablet with a 
cellulose triacetate barrier which functions as a semi permeable membrane. A laser is 
used to form a precision orifice in the barrier, through which the drug is released due 
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to development of osmotic pressure difference across the membrane, when this was 
kept in water. 
 
Figure 1.4: Osmotically controlled release systems. 
5.  Ion Exchange Systems 
These are salts of cationic or anionic exchange resins or insoluble complexes 
in which drug release results from exchange of bound drug ions that are normally 
present in GI fluids. 
1.4. MICROSPHERES                                                                                                         
(shobharani., 2008; Kedar Prasad Meena and Danji J.S., et al., 2011) 
 Microspheres are solid, approximately spherical particles ranging 1-1000µm 
in size. They are made up of polymeric substances, in which the drug is dispersed 
throughout the microsphere matrix. The substances used in the formulation are 
biodegradable synthetic polymers and natural products. The natural polymers of 
choice are albumin and gelatin, the synthetic ones being polylactic acid and 
polyglycolic acid. The polymers used to manufacture microspheres are chosen 
according to their solubility, stability profile, process, safety and economic suitability. 
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                                     Figure 1.5: Microsphere 
Advantages of microsphere delivery system 
•   Protection of unstable, sensitive materials from their environments prior to use. 
•   Better processability (improving solubility, dispersibility, flowability) 
•   Self-life enhancement by preventing degradative reactions. 
•   Safe and convenient handling of toxic materials. 
•   Masking of odor or taste. 
•   Enzyme and microorganism immobilization. 
•   Controlled and targeted drug delivery. 
•   Handling liquids as solids. 
•   To improve bioavailability 
•   To improve the stability 
•   Limiting fluctuation within therapeutic range 
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Applications of microspheres 
Some of the applications of microspheres can be described in detail as given 
below  
1. Prolonged release dosage forms. The microsphere drug can be administered, as 
microsphere is perhaps most useful for the preparation of tablets, capsules or 
parenteral dosage forms. 
2. Microsphere can be used to prepare enteric coated dosage forms, so that the 
medicament will be selectively absorbed in the intestine rather than the stomach. 
3. It can be used to mask the taste of bitter drugs. 
4. From the mechanical point of view, microsphere has been used to aid in the 
addition of oily medicines to tablet dosage forms. This has been used to overcome 
problems inherent in producing tablets from otherwise tacky granulations. This was 
accomplished through improved flow properties. For example, the non-flowable 
multicomponent solid mixture of niacin, riboflavin, and thiamine hydrochloride and 
iron phosphate may be encapsulated and made directly into tablets. 
5. It has been used to protect drugs from environmental hazards such as humidity, 
light, oxygen or heat. Microsphere does not yet provide a perfect barrier for materials, 
which degrade in the presence of oxygen, moisture or heat, however a great degree of 
protection against these elements can be provided. For example, vitamin A and K 
have been shown to be protected from moisture and oxygen through microsphere. 
6. Microsphere can be used to decrease the volatility. An encapsulated volatile 
substance can be stored for longer times without substantial evaporation. 
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7. Microsphere has also been used to decrease potential danger of handling of toxic or 
noxious substances. The toxicity occurred due to handling of fumigants, herbicides, 
insecticides and pesticides have been advantageously decreased after 
microencapsulation. 
8. The hygroscopic properties of many core materials may be reduced by 
microsphere. 
9. Many drugs have been microsphere to reduce gastric irritation. 
10. Microsphere method has also been proposed to prepare intrauterine contraceptive 
device. 
1.5. Classification of polymers used for preparation of microspheres                     
(Vyas S.P., 2002) 
A number of different substances both biodegradable as well as non-
biodegradable have been investigated for the preparation of microspheres. These 
materials include the polymers of natural and synthetic origin and also modified 
natural substances. Some of the polymers used in the preparation of the microspheres 
are classified and listed in Table 1. 
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Table 1.1:  Classification of polymers 
Nature of polymer Classification Examples 
A. Synthetic polymer 
Non biodegradable 
Acrolin 
Glycidal methacrylate 
Epoxy polymers 
Biodegradable 
Lactides and glycosides 
and other copolymers 
Polyalkyl cyano acrylates 
Polyanhydride 
B. Natural polymer 
Protein 
Albumin 
Gelatin 
Collagen 
Polysaccharides 
Chitosan 
Agarose 
Carragenen 
Starch 
Sodium alginate 
Chemically modiffied 
carbohydrates 
Poly(acryl)dextran 
Poly(acryl)starch 
 
 
 
 
Sustained Release Microspheres of Venlafaxine                                           Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur                                                        20 
  
Prerequisites for ideal micosphere carriers 
            The polymer utilized for the preparation of microspheres should ideally fulfill 
the following prerequisites: 
 Longer duration of action 
 Control of content release 
 Increase of therapeutic efficacy 
 Protection of drug 
 Reduction of toxicity 
 Biocompatibility 
 Sterilizability 
 Relative stability 
 Water solubility or dispersability 
 Bioresorbability 
 Targetability 
 Polyvalent 
1.6. PREPARATION METHOD OF MICROSPHERE                   
                                                         (Kedar Prasad Meena and Danji J.S., et al., 2011) 
Preparation of microspheres should satisfy certain criteria 
•   The ability to incorporate reasonably high concentrations of the drug. 
•   Stability of the preparation after synthesis with a clinically acceptable shelf life. 
•   Controlled particle size and dispersability in aqueous vehicles for injection. 
•   Release of active reagent with a good control over a wide time scale. 
•   Biocompatibility with a controllable biodegradability. 
Sustained Release Microspheres of Venlafaxine                                           Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur                                                        21 
  
Preparation of microspheres by any one of the suitable methods like: 
1. Protein gelation technique 
2. Single Emulsion polymerization technique 
3. Double Emulsion polymerization technique 
4. Multiple emulsion polymerization technique 
5. Solvent evaporation technique 
6. Sonication technique 
7. Spray and freeze drying technique 
8. Emulsification-heat stabilization technique 
9. Quasi-emulsion solvent diffusion method of the spherical crystallization technique 
10. Spray congealing 
11. Phase separation coaservation method 
12. Polymerisation technique 
13. Solvent extraction method 
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1. Protein gelation technique 
 
Dissolve egg albumin in distilled 
water 
↓ 
Add drop wise into olive oil to make 
emulsion 
↓ 
From the dropping funnel, emulsion was added drop wise into preheated 
Olive oil (125±50C) 
                         ↓Stir at 1500 rpm 
After heat sterilization for 10 minutes the preparation was cooled to 250C 
          ↓Centrifuge at 2500 rpm, decant the supernatant 
Wash the microspheres with liquid paraffin and twice with ether to obtain a free  
Flowing and discreet product 
↓ 
 Suspended the microspheres in anhydrous ether, stir at 40C in an airtight container 
 
Figure 1.6: Preparation of microspheres by Protein gelation technique. 
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2. Single Emulsion polymerization technique 
Take 100ml of light paraffin oil in glass beaker , mix with 
0.4% w/v span 60 
                                                        ↓Stir and heat at 700C until complete solubilisation 
Cool the mixture at room temperature 
                                                         ↓ 
Drop wise add 10ml of egg albumin aqueous solution of different drug to 
polymer ratio (1:1, 1:5, 1:2) using a 22-gauge hypodermic syringe into external phase 
                                              ↓ Stir light paraffin at 600 rpm for 10 minutes 
A w/o emulsion was formed 
                                              ↓Raise the temperature of oil bath to 950C, 
                                                     stir until microspheres completely dehydrate 
Microspheres thus obtained were decanted, washed 6 times with 20ml 
petroleum ether for 2 minutes at 700 rpm 
                                                         ↓ finally wash 3 times with 60 oz of distilled                  
                                                           water for 2 minutes at 700 rpm, dry at room temp    
                                                           for 24 hour 
After drying, a fine yellow free flowing powders of microsphere were 
obtained that was stored in desiccators at room temperature. 
 
Figure 1.7: Preparation of microspheres by Single emulsion polymerization      
                    technique. 
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3. Double Emulsion polymerization technique 
A double emulsion is usually prepared in two main modes 
Mode 1: One-step emulsification 
In one step emulsification mode a strong mechanical agitation is used for the 
water phase containing a hydrophilic surfactant and an oil phase containing large 
amounts of hydrophobic surfactant. Due to this a W/O emulsion is formed which 
quickly inverts to form a W/O/W double emulsion. 
Mode 2: Two-step emulsification 
A two-step procedure is reported where the primary emulsion can be formed 
as a simple W/O emulsion which emulsion can be formed as a simple W/O emulsion 
which is prepared using water and oil solution with a low HLB (hydrophilic-lipophilic 
balance) surfactant. In the second step, the primary emulsion (W/O) is re-emulsified 
by aqueous solution with a high HLB surfactant to produce a W/O/W double 
emulsion. 
4.   Multiple emulsion polymerization technique 
Multiple emulsion method involves formation of (o/w) Primary emulsion (non 
aqueous drug solution in polymer solution) and then addition of primary emulsion to 
external oily phase to form o/w/o emulsion followed by either addition of cross 
linking agent  (glutaraldehyde) and evaporation of organic solvent. This method of 
preparation is ideal for incorporating poorly aqueous soluble drug, thus enhancing its 
bioavailability.  
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Figure 1.8: Microsphere preparation by multiple emulsion method 
5. Solvent evaporation technique 
A core material to be microencapsulated is dissolved or dispersed in the 
coating polymer solution. With agitation the core material mixture is dispersed in the 
liquid manufacturing vehicle phase to obtain the appropriate size microsphere. The 
mixture is then heated if necessary to evaporate the solvent. The solvent Evaporation 
technique to produce microspheres is applicable to wide variety of core materials. The 
core materials may be either water soluble or water insoluble materials. Solvent 
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evaporation involves the formation of an emulsion between polymer solution and an 
immiscible continuous phase whether aqueous (o/w) or non-aqueous.  
 
Figure 1.9: Basic steps of microsphere by solvent evaporation method 
6. Sonication technique 
As the technique name itself is self explanatory, it just involves a simple 
sonication for certain period of time till a desired size of microspheres are obtained. 
The polymer solution of desired concentration is taken which is sonicated. To this add 
the drug which will then form intrachain cross-link with cysteine residues of polymer 
chains. Prepared a stable preparation of air filled human polymer microspheres 
(Albunex) by sonication technique. The microspheres ranged in size from 1-10m with 
99% of particles smaller than 10 m. The mean size was 5 m, which is small enough to 
pass freely through the pulmonary capillary circulation. 
7.  Spray drying technique 
In Spray Drying the polymer is first dissolved in a suitable volatile organic 
solvent such as dichloromethane, Acetone, etc. The drug in the solid form is then 
dispersed in the polymer solution under high-speed homogenization. This dispersion 
is then atomized in a stream of hot air. The atomization leads to the formation of the 
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small droplets or the fine mist from which the solvent evaporate instantaneously 
leading the formation of the microspheres in a size range 1-100m.  
 
Figure 1.10: Main process stages involved in spray drying process. 
 
Figure 1.11: Formation of product in spray drying. 
Principle 
There are three fundamental steps involved in spray drying 
1) Atomization of a liquid feed into fine droplets. 
2) Mixing of these spray droplets with a heated gas stream, allowing the liquid to 
evaporate and leave dried solids. 
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3) Dried powder is separated from the gas stream and collected. Spray drying involves 
the atomization of a liquid feedstock into a spray of droplets and contacting the 
droplets with hot air in a drying chamber. 
The sprays are produces by either rotary (wheel) or nozzle atomizers. 
Evaporation of moisture from the droplets and formation of dry particles proceed 
under controlled temperature and airflow conditions. Powder is discharged 
continuously from the drying chamber. Operating conditions and dryer design are 
selected according to the drying characteristics of the product and powder 
specification. 
8. Emulsification-heat stabilization technique 
5% solution of BSA containing 0.1% Tween80 was made, to which 4% drug 
was added and used as the aqueous phase. The oil phase composed of 30 ml maize oil 
and 10 ml petroleum ether with 1% Span 80 as emulsifier were mixed together and 
allowed to stir for 10 min at 1000 rpm. The aqueous phase was added drop wise to the 
oil phase and stirred on a magnet stirrer at 1000 rpm for 30 min to form the initial 
emulsion. This emulsion was then added to 40 ml of maize oil preheated to 120° C 
and stirred at 1000 rpm for 15 min to allow the formation and solidification of 
microspheres. The microsphere suspension was centrifuged at 3500 rpm for 30 min 
and the settled microspheres were washed three times with ether to remove traces of 
oil on microsphere surfaces. The microspheres were vacuum dried in desiccators 
overnight and stored were vacuum dried in a desiccators overnight and stored at 4°C 
in dark. The microspheres had mean diameters between 1-25 m of which more than 
50 percent were below 5 m.  
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9.  Quasi-emulsion solvent diffusion method of the spherical crystallization 
technique. 
Development and characterization of sustained release microspheres by quasi 
emulsion solvent diffusion method. The microspheres were prepared using the 
quasiemulsion solvent diffusion method of the spherical crystallization technique. 
Drug and polymer were dissolved completely in the acetone–dichloromethane 
mixture. Then Aerosil was suspended uniformly in the drug– polymer solution under 
vigorous agitation. The resultant drug–polymer–Aerosil suspension was poured into 
the distilled water (150 ml) containing 0.08% of SDS (i.e. poor solvent) under a 
moderate agitation   (450–750rpm) and thermally controlled at 0–38°C. The 
suspension was finely dispersed into quasi-emulsion droplets immediately under 
agitation, and the drug and polymers co precipitated in the emulsion droplets. After 
agitating the system for 20 min, 150 ml of poor solvent was added slowly to promote 
the diffusion of the good solvent from emulsion droplets into poor solvent resulting in 
enhancement of the solidification of quasiemulsion droplets.  
10.  Spray congealing 
The polymer is first dissolved in a suitable volatile organic solvent such as 
dichloromethane, acetone, etc. The drug in the solid form is then dispersed in the 
polymer solution under high speed homogenization. This dispersion is then atomized 
in a stream of cold air. The atomization leads to the formation of the small droplets or 
the fine mist from which the solvent evaporates instantaneously leading the formation 
of the microspheres in a size range 1-100 m. 
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11. Phase separation coacervation technique 
This process is based on the principle of decreasing the solubility of the 
polymer in organic phase to affect the formation of polymer rich phase called the 
coacervates. In this method, the drug particles are dispersed in a solution of the 
polymer and an incompatible polymer is added to the system which makes first 
polymer to phase separate and engulf the drug particles. Addition of non-solvent 
results in the solidification of polymer. Poly lactic acid (PLA) microspheres have 
been prepared by this method by using butadiene as incompatible polymer. The 
process variables are very important since the rate of achieving the coacervates 
determines the distribution of the polymer film, the particle size and agglomeration of 
the formed particles. The agglomeration must be avoided by stirring the suspension 
using a suitable speed stirrer since as the process of microspheres formation begins 
the formed polymerize globules start to stick and form the agglomerates. Therefore 
the process variables are critical as they control the kinetic of the formed particles 
since there is no defined state of equilibrium attainment 
12. Polymerization techniques 
The polymerization techniques conventionally used for the preparation of the 
microspheres are mainly classified as:  
I. Normal polymerization 
II. Interfacial polymerization. Both are carried out in liquid phase. 
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•   Normal polymerization 
It is carried out using different techniques as bulk, suspension, precipitation, 
emulsion and micellar polymerization processes. In bulk, a monomer or a mixture of 
monomers along with the initiator or catalyst is usually heated to initiate 
polymerization. Polymer so obtained may be moulded as microspheres. Drug loading 
may be done during the process of polymerization. Suspension polymerization also 
referred as bead or pearl polymerization. Here it is carried out by heating the 
monomer or mixture of monomers as droplets dispersion in a continuous aqueous 
phase. The droplets may also contain an initiator and other additives. Emulsion 
polymerization differs from suspension polymerization as due to the presence initiator 
in the aqueous phase, which later on diffuses to the surface of micelles. Bulk 
polymerization has an advantage of formation of pure polymers. 
•   Interfacial polymerization 
It involves the reaction of various monomers at the interface between the two 
immiscible liquid phases to form a film of polymer that essentially envelops the 
dispersed phase 
13. Solvent extraction 
The contaminants are separated from the solvent either by changing the 
pressure and temperature, by using a second solvent to pull the first solvent out of the 
solvent/contaminant mixture, or by other physical separation processes. At the 
completion of this step, concentrated contaminants result. Concentrated contaminants 
are removed during the separation process, and the solvent is sent to a holding tank 
for reuse. The contaminants are then analyzed to determine their suitability for 
recycle/reuse, or need for further treatment before disposal. 
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                                Figure 1.12: Microsphere preparation by solvent extraction. 
Loading of drug (vyas s.p., 2002)  
The active components are loaded over the microspheres principally using two 
methods. I.e. during the preparation of the microsphere or after the formulation of the 
microsphere by incubating them with the drug/protein. The active component can be 
loaded by means of the physical entrapment, chemical linkage and surface absorption. 
The entrapment largely depends on the method of preparation and nature of the drug 
or polymer.  
Maximum loading can be achieved by incorporating the drug during the time 
of preparation but it may get affected by many other process variables such as method 
of preparation, presence of additives, heat of polymerization, agitation intensity, etc. 
The loading is carried out in pre-formed microspheres by incubating them 
with high concentration of the drug in a suitable solvent. The drug in these 
microspheres loaded via penetration or diffusion of the drug through the pores in the 
microspheres as well as adsorption on the surface. The drugs and protein can also be 
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incorporated by physical or chemical linkage. The absorption of the drug/proteins 
depends on the nature of the polymers. 
1.7. DRUG RELEASE KINETICS 
Release of the active constituent is an important consideration in case of 
microspheres. Many theoretically possible mechanisms may be considered for the 
release of drug from the microspheres. 
1. Liberation due to polymer erosion or degradation, 
2. Self diffusion through the pore, 
3. Release from the surface of the polymer, 
4. Pulsed delivery initiated by the application of an oscillating or sonic field. 
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FACTORS INFLUENCING PROPERTIES OF MICROSPHERES.           
(Kedar Prasad Meena and Danji J.S.,et al.,  2011) 
 
(A) Dispersed phase 
1. Polymers commonly used to form microspheres 
2. Choice of solvent 
(1) Should be able to dissolve the chosen polymer; 
(2) Poorly soluble in the continuous phase; 
(3) High volatility and a low boiling point; 
(4) Low toxicity. 
(5) Alternative components (dispersed phase) 
(a) Co-solvent:- organic solvents miscible with water such as methanol   and ethanol. 
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(b) Porosity generator:- increases the degradation rate of polymer and improves drug 
release rate.  E.g. Incorporating sephadex (cross-linked dextran gel) into insulin–pla 
microspheres significantly increases microsphere porosity. 
(B) Continuous phase 
(a) Surfactant:- 
•   It reduces the surface tension of continuous phase. 
•   Avoids the coalescence and agglomeration of drops. 
•   Stabilizes the emulsion. 
•   Widely used stabilizers include: 
i. Non-ionic: partially hydrolyzed poly vinyl alcohol, methylcellulose, tween, span 
ii. anionic: sodium dodecyl sulphate (sds), sodium lauryl sulphate. 
iii. cationic: cetyltrimethyl ammonium bromide (ctab). 
(b) Alternative component:- 
•   Antifoaming agent - foaming problem will disturb the formation of microspheres. 
•   Anti-foams of silicon and non-silicon constituents are used. 
(C) Impact of parameters and operating conditions on the properties of microspheres. 
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Technology limitations in preparing microspheres 
•   Residual solvents 
•   Stability 
•   Non availability of degradable, synthetic polymers 
•   Encapsulation efficiency 
•   Limitation of manufacturing process 
•   Sterilization 
1.8. DEPRESSION (http://www.about.com) 
Depression makes a person feel sad, hopeless, worthless, pessimistic and 
guilty. Often the sufferer has difficulty concentrating and making decisions, has a loss 
of appetite and weight or a weight gain, has difficulty sleeping, has a lack of energy 
and sometimes physical symptoms such as slow movement and speech. Depression 
must be taken seriously because of the high rate of suicide associated with it. 
 Most common types of depression  
The following are descriptions of the most common types of depression. 
1. Major Depressive Disorder 
When people use the terms depression or clinical depression, they are 
generally referring to major depressive disorder. Major depressive disorder is a mood 
disorder characterized by a depressed mood, a lack of interest in activities normally 
enjoyed, changes in weight and sleep, fatigue, feelings of worthlessness and guilt, 
difficulty concentrating and thoughts of death and suicide. If a person experiences the 
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majority of these symptoms for longer than a two-week period, they may be 
diagnosed with major depressive disorder.  
2. Dysthymic Disorder 
Dysthymia (pronounced Dis-THIGH-me-uh) comes from the Greek roots dys, 
meaning "ill" or "bad," and thymia, meaning "mind" or "emotions." The terms 
dysthymia and dysthymic disorder refer to a mild to moderate, chronic state of 
depression.  
3. Bipolar Disorder 
Bipolar disorder is an illness that consists of alternating periods of elevated 
moods, called manic episodes, and depression. Mood swing run on a spectrum from 
mild mania (called hypomania) to more severe, debilitating highs. Periods of mania 
can last for hours, days, weeks or even months before depression returns.  
4. Postpartum Depression 
Pregnancy brings about many hormonal shifts. These dramatic shifts can 
sometimes affect mood. This is commonly known as the "baby blues." Postpartum 
depression can be more than just a case of the blues, however. It can range from mild 
symptoms that go away without treatment all the way up to postpartum psychosis, 
which left untreated, may be responsible for tragic murders of children.  
5. Seasonal Affective Disorder 
If you experience depression, sleepiness, weight gain and carbohydrate 
cravings during the winter months, but feel great as soon as spring returns, you may 
have a condition called Seasonal Affective Disorder (SAD).  
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6. Premenstrual Dysphoric Disorder 
The most frequently reported symptoms of premenstrual syndrome (PMS) 
include irritability, fatigue, anxiety, nervous tension, mood swings, depression, 
feeling overwhelmed or out of control, physical symptoms of swelling or bloating of 
the abdomen or extremities, appetite changes and food cravings, aches, and breast 
tenderness. These symptoms may occur for several days to 2 weeks before menses but 
subside with the onset of the menstrual period. When these symptoms, especially 
those of mood, are severe, a diagnosis of premenstrual dysphoric disorder (PMDD) 
may be made.  
7. Atypical Depression 
Do you experience symptoms such as improved mood when good things 
happen, overeating, sleeping too much or sensitivity to rejection? These are symptoms 
characteristic of atypical depression, which is a type of depression which does not 
follow the "typical" set of depression symptoms, such as a lack of appetite and 
insomnia. It is actually more common than the name might imply.  
Etiology of depressions   
 Though there are several theories about what cause classical depressions, 5-
HT plays an important role in the genesis of depressive psychosis as evidenced by 
increasing in 5-HT (or) its precursors in the brain in patients of depressive psychosis. 
Many drugs (antidepressants) based on 5-HT metabolization and activations are now 
available. They prevent the uptake of 5-HT from serotonergic nerve endings, thereby 
increasing endogeneous 5-HT levels. 
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 Similarly, noradrenaline (NAD) also plays an important role in the genesis of 
depression as its absence in various areas of the CNS leads to the development of 
depressions. Antidepressant like MAO and SNRI act by inhibiting the metabolism of 
NAD (or) preventing its reuptake into the adrenergic nerve ending. 
Symptoms and Signs of Depression  
Depression is not something you feel for a day or two before feeling better. In 
true depressive illnesses, the symptoms last weeks, months, or sometimes years if you 
don't seek treatment. If you are depressed, you are often unable to perform daily 
activities. You may not care enough to get out of bed or get dressed, much less work, 
do errands, or socialize. 
 Adults: You may be said to be suffering from a major depressive episode if 
you have a depressed mood for at least two weeks and have at least five of the 
following clinical symptoms: 
o Feeling sad or blue 
o Crying spells 
o Loss of interest or pleasure in usual activities 
o Significant increase or decrease in appetite 
o Significant weight loss or weight gain 
o Change in sleep pattern: inability to sleep or excessive sleeping 
o Agitation or irritability 
o Fatigue or loss of energy 
o A tendency to isolate from friends and family 
o Trouble concentrating 
o Feelings of worthlessness or excessive guilt 
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o Thoughts of death or suicide 
Facts/Statistics of Depression 
 Depression affects about 19 million Americans annually. It is estimated to 
contribute to half of all suicides. About 5%-10% of women and 2%-5% of men will 
experience at least one major depressive episode during their adult life. Depression 
affects people of genders, as well as all races, incomes, ages, and ethnic and religious 
backgrounds. However, it is twice as common in women compared to men and three 
to five times more common in the elderly than in young people 
1.9. DIAGNOSIS OF DEPRESSION 
Many providers of health care may help diagnose clinical depression: licensed 
mental-health therapists, family physicians, or other primary-care providers, 
specialists whom you see for a medical condition, emergency physicians, 
psychiatrists, psychologists, psychiatric nurses, and social workers. 
If one of these professionals suspects that you have depression, you will 
undergo an extensive medical interview and physical examination. As part of this 
examination, you may be asked a series of questions from a standardized 
questionnaire or self-test to help assess your risk of depression and suicide. 
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Depression may be associated with a number of other medical conditions or 
can be a side effect of various medications. For this reason, routine laboratory tests 
are often performed during the initial evaluation to rule out other causes of your 
symptoms. Occasionally, an X-ray, scan, or other imaging study may be needed 
Treatment of Depression 
If your symptoms indicate that you have clinical depression, your health-care 
provider will strongly recommend treatment. Treatment may include addressing any 
medical conditions that cause or worsen depression. For example, an individual who 
is found to have low levels of thyroid hormone might receive thyroid hormone 
replacement with levothyroxine (Synthroid, Levoxyl). Other components of treatment 
may be supportive therapy, such as changes in lifestyle and behavior, psychotherapy, 
complementary therapies, and may often include medication. If your symptoms of 
depression are severe enough to warrant treatment with medication, you are most 
likely to feel better faster and for longer when medication treatment is combined with 
psychotherapy. 
Most practitioners will continue treatment of major depression for six months 
to a year. Treatment for teens with depression can have a significantly positive effect 
on the adolescent's functioning with peers, family, and at school. Without treatment, 
your symptoms will last much longer and may never get better. In fact, they may get 
worse. With treatment, your chances of recovery are quite good.  
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Prevention of Depression 
People who have risk factors for depression should be "screened" regularly by 
their health-care provider. This means that when they see their health-care provider, 
questions should be asked that might indicate depression. 
If identified early, those who are at risk for depression are more likely to 
benefit from treatment.                 
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2. NEED AND OBJECTIVE 
 
There are various approaches in delivering a therapeutic substance to the 
target site in a sustained or controlled release fashion. One such approach is using 
microspheres as carrier for drugs. Microspheres of biodegradable and non-
biodegradable polymers have been investigated for sustained release depending on the 
final application. In the case of non-biodegradable drug carriers, when administered 
parenterally, the carrier remaining in the body after the drug is completely released 
possess the possibility of carrier toxicity over a long period of time. Biodegradable 
carriers which degrade in the body to non-toxic degradation products do not possess 
the problem of carrier toxicity and are more suited for parenteral application. Thus, 
emphasis in this review is on the approach of using biodegradable microspheres for 
achieving sustained release.    
Microsphere formulation offers a number of advantages in therapeutics where 
the sustained release of drugs as well as predictable and reproducible drug release 
kinetics is important factors among them. Venlafaxine Hydrochloride is the most 
widely used anti- depressant agent in the treatment of major depression disease has a 
low bioavailability, because of its poor absorption. It undergoes hepatic metabolism 
and its mean elimination half life 5 hours. The aim of the present work was to 
formulate by using natural gum like chitosan, sodium alginate and xanthan gum 
microsphere containing Venlafaxine Hydrochloride in order to provide a prolonged 
effect and relatively constant effective level of these drugs in the treatment of major 
depression disease. 
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Objectives  
 To reduced dosing frequency and improved patient compliance.      
 To optimize the concentration of drug-polymer ratio for suitable 
formulation. 
 To characterize the microsphere for its physiochemical properties. 
 To evaluate the microsphere for surface characterization with DSC for 
drug-polymer compatibility study and FTIR for identification of drug. 
 To determine the effect of enteric coated microspheres in protecting 
drug release in acidic media (pH1.2) using 0.1 HCL. 
 To determine the invitro release efficiency of microspheres for 
releasing at buffer 7.4 pH determine the percentage of drug release. 
 In- vitro drug release kinetic study for release mechanism by the best 
fit model.  
 To perform stability studies as per ICH guidelines. 
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3. PLAN OF WORK 
 
 LITERATURE  REVIEW 
 SELECTION OF DRUG AND EXCIPIENTS 
 EXPERIMENTAL WORK 
A) PREFORMULATION STUDY 
 Identification of drug 
o By FTIR spectroscopy 
o By melting point 
 Physicochemical parameters 
o Organoleptic properties  
o Solubility profile 
o Loss on drying 
   Analytical methods 
o Determination  of λmax 
o Development  of standard curve of  
venlafaxine Hydrochloride 
o Determination of percentage purity of drug 
   Determination of compatibility for drug with polymer 
o By DSC thermal analysis 
             B)  PREPARATION OF SUSTAINED RELEASE MICROSPHERES 
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 C)  EVALUATION OF SUSTAINED RELEASE MICROSPHERES 
 Percentage yield 
 Drug content 
 Entrapment efficiency 
 Particle size analysis 
 SEM 
 In vitro dissolution studies 
 Kinetics of In vitro drug release 
 D)  STABILITY STUDY 
 RESULTS AND DISCUSSION 
 CONCLUSION 
 FUTURE PROSPECTS 
 BIBLIOGRAPHY 
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4. REVIEW OF LITERATURE 
 
Adimoolam Senthil  et al., (2010) reported that was to formulate and evaluate 
the  mucoadhesive Venlafaxine  HCl  microspheres using  Hydroxy propyl  methyl  
cellulose  K4M  as  polymer.  Venlafaxine  HCl  is  a  new  generation  serotonin  
reuptake  inhibitor  drug  showing  effective antidepressant properties, having  a  
short  bioavailability  of  12.6% and biological  half-life of  5  hours. Venlafaxine  
HCl  microspheres  were prepared by simple emulsification phase separation 
technique using glutaraldehyde as a crosslinking agent. From those fifteen 
preliminary trial batches, the optimized formulation was selected based on the 
percentage of mucoadhesion and sphericity of microspheres. On the basis of the 
preliminary trials, 32 full factorial design was employed to study the effect of 
independent variable X1 (polymer-to- drug ratio 1:1, 3:1 and 6:1) and the stirring 
speed X2 (500, 1000 and 1500rpm) on the dependent variables  like  percentage 
mucoadhesion,  drug entrapment efficiency, particle size and t80.  The drug polymer 
compatibility  studies  were  carried  out  using FTIR.  As the concentration of 
glutaraldehyde increased, the mucoadhesiveness decreases and there was no 
significant effect in time. Stirring speed has negative effect on t80.  
Anita Verma., et al., (2010) have studied preparation of methacrylate for 
delivery of ketorolac tromethamine via the oral route. Drugs were encapsulated within 
polymethacrylate copolymer Eudragit RS100 and Eudragit RL100, by solvent 
evaporation method. Magnesium sterate was used as droplet stabilizer in 
concentration of 0.3(v/v). Selected formulations were characterized for their 
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entrapment efficiency, particle size, surface morphology and release behaviour. 
Invitro dissolution tests were performed by using dissolution media with two different 
pH. All the selected formulations exhibited a prolonged release for almost 24 hour. 
This study indicated that Eudragit microspheres containing ketorolac tromethamine 
could be prepared successfully by using an emulsion solvent evaporation technique, 
which would not only sustain the release of drug but also minimize the side effects of 
this drug. 
Barish., et al., (2010) have developed oral sustained release microspheres of 
Cefazolin sodium to attain prolonged action, which can reduce its side effects and 
provide more safety and efficacy. The microspheres were formulated by solvent 
evaporation method using the polymer Guar gum. Five formulations were prepared 
with 1:1, 1:2, 1:3, 1:4, 1:5 drugs: polymer ratio. They were comparatively evaluated 
for their better release profile. 
Bindhu madhavi., et al., (2009) have reported a new class of antidepressants. 
Its higher solubility in water results in burst effect with sudden peak levels of drug in 
blood. The half lives of venlafaxine and its active metabolite O-desmethyl venlafaxine 
are 5 hour and 11 hour respectively. The micro beads were prepared by the ionotropic 
gelation of sodium alginate in calcium chloride solution. The prepared micro beads 
were evaluated mainly for the  sustain release of the drug apart from the other tests 
like, % drug encapsulation, particle size and drug polymer compatibility by the FTIR 
studies. 
Bindhu Madhavi  B., et al., (2011) reported that venalafaxine hydrochloride 
is the free soluble with antidepressant activity. Being highly soluble drug there is 
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possibility of burst effect which causes sudden peak level of drug in blood. To reduce 
the adverse effects due to burst effect and to have the sustain action of the drug we 
have prepared the ethyl cellulose microsphere of the drug. The drug release was found 
to be sustained for 16 hours and was found to follow the peppas kinetics. 
Bipul N., et al.,(2009)  have developed microencapsulated controlled release 
preparations of a highly water/soluble drug, salbutamol sulphate by (water in oil) in 
oil emulsion technique using ethyl cellulose as the retardant material. Various 
processing and formulation parameters such as drug/polymer ratio, stirring speed, 
volume of processing medium were optimized to maximize the entrapment. The 
prepared microspheres were characterized for their micromeritic properties and drug 
loading, as well as compatibility by infrared spectroscopy, differential scanning 
calorimetry (DSC), X-ray powder diffractometry and scanning electron microscopy 
(SEM). 
Dhanraju M.D., et al., (2010) concluded that the microspheres were 
evaluated based on average particle size by optical microscopy, surface morphology 
by scanning electron microscopy (SEM) and in vitro drug release. The drug - polymer 
interactions and the effect on drug crystalline due to the incorporation of 
Indomethacin in polymer matrix have been evaluated by differential scanning 
calorimetry (DSC) and thin layer chromatography studies. The in vitro release studies 
were performed in phosphate buffer medium pH 7.2. The microspheres fabricated by 
emulsion solvent evaporation method had average particle size of about 35µ and 
observed to have a spherical shape with smooth surface. 
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Kannan., et al., (2009) have developed sustained release microcapsules of 
Acetazolamide, a short half life carbonic anhydrase inhibitor, was developed to 
reduce the frequency of drug administration, ease of dose adjustment and improve 
patient compliance. The result showed that the encapsulation efficiencies were desired 
for all the formulations of microcapsules developed. Particle sizes of the 
microcapsules were influenced by the concentration of Eudragit and stirring speed. 
Kedar Prasad Meena., et al., (2011) concluded that Microspheres are 
characteristically free flowing powders consisting of proteins or synthetic polymers 
which are biodegradable in nature and ideally having a particle size less than 200 μm. 
A well designed controlled drug delivery system can overcome some of the problems 
of conventional therapy and enhance the therapeutic efficacy of a given drug. There 
are various approaches in delivering a therapeutic substance to the target site ina 
sustained controlled release fashion. One such approach is using microspheres as 
carriers for drugs. It is there liable means to deliver the drug to the target site with 
specificity, if modified, and to maintain the desired concentration at the site of interest 
without untoward effects. Microspheres received much attention not only for 
prolonged release, but also for targeting of anticancer drugs to the tumor. In future by 
combining various other strategies, microspheres will find the central place in novel 
drug delivery, particularly in diseased cell sorting, diagnostics, gene & genetic 
materials, safe, targeted and effective in vivo delivery and supplements as miniature 
versions of diseased organ and tissues in the body. 
Kishore Kumar Reddy  k., et al., (2011) have studied the microspheres have 
been utilized to obtain prolonged and uniform release in the stomach for development 
of once daily a formulation. The major advantage of the preparation technique 
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includes, Short processing time, the lack of exposure of the ingredients to high 
temperature, high encapsulation efficiencies. The formulated metformin loaded 
microspheres by solvent evaporation method by using aqueous medium as processing 
and tried to evaluate them for various in vitro characterization parameters. 
Kumar Darapu B.N., et al., (2011) prepared floating microspheres of 
Ranitidine Hydrochloride with HPMC K 100, Xanthan gum and Eudragit S100 and in 
various ratios of 1: 1, 1: 2, and 1: 3. The formulations were evaluated for FTIR, drug 
loading, % entrapment, particle size, SEM, buoyancy, dissolution study and the drug 
release kinetics. The enhanced floatability of the formulation and its retention in GIT 
may attribute for the increased bioavailability and decrease in frequency of 
administration. Comparison of three polymers revealed HPMC to be a suitable 
candidate for sustained release. 
Lakshmana Prabu., et al., (2009) have developed Aceclofenac was micro 
encapsulated using rosin o/w emulsion solvent evaporation technique. The effect of 
three formulation variables including the drug: polymer ratio, emulsifier (polyvinyl 
alcohol) concentration and organic solvent (dichloromethane) volume were examined. 
The prepared batches were characterized for microspheres particle size distribution, 
encapsulation efficiency and invitro release behavior. The study reveals that drug: 
polymer ratio had considerable effect on the entrapment efficiency, however particle 
size distribution of microspheres rather than on the drug: polymer ratio. 
Mohanraj Palanisamy., et al., (2009) have reported metoprolol tartrate 
formulated as biodegradable microspheres using chitosan by the phase separation 
emulsification technique. Microspheres of 1:0.5 to 1:2 drugs to carrier ratios were 
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prepared and thermally cross linked. Drug to carrier ratio 1:1 showed maximum 
percentage yield and highest drug entrapment. The size range of the microspheres 
varies from 3.5 to 31.5μm. UVand DSC studies were carried out to confirm the 
presence and stability of the drug in the microsphere short time stability studies were 
carried out different temperatures. Invitro release studies were carried out different pH 
for period of 10 hour and compare with pure drug. The release of metoprolol tartrate 
from the chitosan microsphere was found to be sustained. 
Nair Sagjisha ., et al., (2010) have developed formulation and evaluation of 
microspheres with repaglinide as model drug for prolongation of drug release time. 
An attempt was made to prepare microspheres of repaglinide by quasi emulsion 
solvent diffusion technique with a view to deliver the drug at sustained or controlled 
manner in gastrointestinal tract and consequence in systemic circulation. The 
microspheres were formulated by using various concentrations of HPMC, Ethyl 
cellulose and Eudragit RSPO as a retarding agent to control the release rate. Invitro 
release studies indicated that, as the concentration of retarding agent increase the 
formulation become more sustained. 
Nappinai M., et al., (2011) have developed using combination of 
polyethylene glycol 6000 and Eudragit RS 100 and Eudragit RS 100 alone by solvent 
evaporation method and non-solvent addition method with an aim to prolong its 
release. The microspheres were spherical, discrete and compact and size distribution 
was between 4 to 24μm. Invitro studies are carried out at different pH for a period of 
12 hours and compared with marketed formulation. The analysis of regression values 
of Higuchi plot and Korsemeyer-peppas plot and n values of Korsemeyer-peppas 
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model suggested a combination of diffusion and dissolutional mechanism indicating 
the drug release from the formulations was controlled by more than one processes. 
Nikil Karani  A., et al., (2009) have reported new, simple and cost effective 
uv-spectrophotometric method was developed for the estimation of venlafaxine 
hydrochloride in bulk and pharmaceutical formulation venlafaxine hydrochloride was 
estimated at 225.27 nm in distilled water. Linearity range was found to be 3.4x104  
mol-1 cm in distilled water. These methods were tested and validated for various 
parameters according to ICH guidelines and USP. The results demonstrated that the 
procedure is accurate, precise and reproducible while being simple, cheap and less 
time consuming and can be suitably applied for the estimation of venlafaxine 
hydrochloride in different dosage form and dissolution studies. 
Phalguna Y., et al., (2010) have developed in the present study was made to 
formulate zidovudine as microparticulate drug delivery system in order to localize 
drug at the absorption site, enhance its bioavailability, reduce dose, thereby improving 
patient compliance. Microparticulate system of zidovudine was formulated using 
HPMC as carrier by emulsification heat stabilizing method. Preformulatuion studies 
were carried out in order to establish compatability between drug and polymer by IR 
spectroscopy. These formulation were subjected to various evaluation parameters like 
% practical yield, drug entrapment efficiency, particle size distribution, in-vitro 
release studies and stability studies. 
Prasant  K., et al., (2009) have reported  the  microspheres  were  found  to  
be  discrete, spherical with free flowing properties. The morphology (Scanning 
Electron Microscopy), particle size distribution, entrapment efficiency and their  
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release profiles  were investigated. The percentage yield was found to be maximum  
in case of solvent evaporation method. The  mean  geometric  particle  size  of  
microspheres  prepared  by  solvent  evaporation method was  found  in  the  ranges  
of  40-50µm  and  the microspheres  prepared  by W/O emulsion  solvent  evaporation  
method  was  found  in  a  ranges  of  126-150 µm, respectively.   
Rajamanikam Daveswaran., et al., (2010) have reported sustained release 
microspheres of Aceclofenac using egg albumin as release retarding agent. The results 
of FTIR spectral and DSC studies showed that there was no significant interaction 
between the drug and polymer. The maximum yield of the microspheres was found to 
be 96.99% and the encapsulation efficiency was found to be 65.2%. The prepared 
albumin microspheres released the drug completely within 10 hours at lower drug to 
polymer ratio. The prepared microspheres showed minor change in drug content 
proving good stability of the product conducted both in accelerated and long term 
stability studies.  
Senthil A., et al., (2011) have reported mefenamic acid is a potent non-
steroidal anti-inflammatory drug, has low oral bioavailability due to poor aqueous 
solubility and insufficient dissolution, so it is used in high dose which leads to adverse 
drug reactions (ADRS) associated with NSAIDS such as gastrointestinal (GI) effects 
and renal effects of the agents. The formulations were characterized for their 
entrapment efficiency, particle size, surface morphology and release behaviour. The 
mean particle size of microspheres ranged from 75 to 225 μm and encapsulation 
efficiency ranged from 72.72 to 95.88% (w/w). 
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Shivakumar H.N., et al., (2011) investigated the microcapsule size was found 
to increase with increased polymer loads and decrease with decreased polymer loads 
and size decrease with increase span-80 concentrations. The microencapsulation 
efficiency was found to depend on the initial polymer loads and the concentration of 
span-80 employed during emulsification. The increase in the drug encapsulation with 
increase in the span-80 level could also ascribed to the emulsifying effect of the 
surfactant which helped the drug to be finely dispersed and embedded in the polymer 
matrix prior encapsulation. 
Sindhuri P., et al., (2011) have reported Norfloxacin a fluroquinoline 
derivative used as antibiotic requires multiple administration of drug, leading to 
fluctuation in plasma concentration. Norfloxacin microsphere by using various 
polymers like carbopol 934, sodium carboxy methyl cellulose (scmc) using different 
drug: polymer ratios. The prepared Norfloxacin microspheres showed good flow 
properties showed sustained release of the drug from the formulations for a period of 
12 hours. 
Sudhamani., et al., (2010) have developed as microspheres by using ethyl 
cellulose as carrier. These ethyl cellulose microspheres were prepared by the solvent 
evaporation method. The prepared microspheres were subjected to various evaluation 
and Invitro release studies. Highest percentage of loading was obtained by increasing 
the amount to polymer. The particle sizes of the prepared microspheres were 
determined by optical microscopy and SEM analysis. The Invitro release studies 
showed that ibuprofen microspheres of 1:2 ratios showed better sustained effect over 
a period of 8 hours. 
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Sunitha S., et al., (2010) have been reported sustained release microspheres of 
tramadol hydrochloride were formulated using a enteric polymers like cellulose 
acetate phthalate (CAP),cellulose acetate (CA) and ethyl cellulose (EC) by emulsion 
solvent evaporation technique. The microspheres were characterized for particle size, 
flow properties, percentage yield, scanning electrom microspcopy (SEM) and drug 
entrapment. The results obtained were found in desired range where the drug 
entrapment efficiency of microspheres was found to be ranging from 61.54% to 
86.95%, size of microspheres found in the range 341µm to 608µm. The drug release 
was extended up to 12 hours with CAP and EC and maximum release retardation was 
found in the formulation with EC(formulation F3) FTIR and XRD results showed that 
tramadol is compatable with excipients. 
Tamizharasi S., et al., (2011) designed drug therapy is to achieve a desire 
concentration of the drug in blood or tissue which is therapeutically effective and 
nontoxic for extended period of time, and this goal can be achieved by proper design 
of sustain release dosage regimen of the various biodegradable polymers used for the 
development of sustained release formulations, poly caprolactone has been reported to 
be advantageous since they are biocompatible and suitable for controlled drug 
delivery due to high permeability to many drugs and at the same time being free from 
toxicity. 
Thomas L., et al., (2009) have reported the antibiotic drug (erythromycin) to 
provide sustained release delivery system. Coarse containing Erythromycin as a 
model drug was prepared by emulsion solvent evaporation technique using different 
ratios of drug and polymer (ethyl cellulose). The prepared microspheres were 
subjected to drug loading, In-vitro drug release as well as scanning electron 
Sustained Release Microspheres of Venlafaxine                                                       Review of literature  
 
Adhiparasakthi College of Pharmacy, Melmaruvathur 57 
microscopy. The drug loaded microspheres shows 70-85% drug entrapment. In-vitro 
drug release studies were carried out up to 12-18hours in phosphate buffer (pH-7.4) at 
480nm. 
Venkatesan P., et al., (2011) concluded that formulate and evaluate the 
loxoprofen loaded Sustained release microspheres by emulsion solvent evaporation 
technique. Ethylcellulose, a biocompatible polymer is used as the retardant material. 
The prepared microspheres were characterized for their particle size and drug loading 
and drug release. The in-vitro release studies were carried out in phosphate buffer at 
pH 7.4. The prepared microspheres were white, free flowing and spherical in shape. 
The drug-loaded microspheres showed 71.2% of entrapment and the in-vitro release 
studies showed that Loxoprofen microspheres of 1:3 ratios showed better sustained 
effect over a period of 8 hours. 
Vikram Deshmukh., et  al., (2011) have reported the present investigation is 
aimed to prepare the sustained release beads of carbamazepine using different 
proportions of talc and sodium alginate for sustained delivery  of carbamazepine. The 
proposed beads were formulated using the iontropic gelation method. The drug to talc 
to polymer ratio in optimized batch S2 was kept at 1: 0.5: 0.3. The obtained   beads 
were characterized for its particle size distribution, percent drug  content, mean 
diameter and crushing strength, thermal analysis (DSC), crystallinity, surface 
morphology (SEM), and  in  vitro drug release. Further investigations are required to 
reduce the amount of polymer in microspheres that can provide maximum drug 
loading and acceptable dosage form. 
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Vimala Shirvi D., et al., (2010) have developed for the estimation of 
venlafaxine hydrochloride in raw material and pharmaceutical dosage form. In this 
method venlafaxine hydrochloride showed zero crossing at 274 nm, with a sharp peak 
at 285 nm. Beers law was obeyed in the concentration range of 40-120 μg/ml. The 
limit of detection and limit of quantification were found to be 1.82μg/ml and 
5.49μg/ml respectively. The method was successfully applied to the determined of 
venlafaxine hydrochloride in tablet. 
Yadav N., et al., (2011) have reported the micro particles can be prepared by 
using any one of the several techniques but choice of the technique mainly depends on 
the nature of the polymer used, the drug and the duration of the therapy. Atenolol 
microspheres synthesized by solvent evaporation method in which the different 
concentration ranges of Atenolol and ethyl cellulose polymer were taken. The reaction 
mechanism to form sustained release Atenolol microspheres were determined by 
optical microscopic method and evaluated by using FT-IR spectroscopy. The particle 
size of Atenolol ranged from 80 to 186 µm. The size of particle was observed to 
increase with increasing concentration.  
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5.1. DRUG PROFILE 
VENLAFAXINE HYDROCHLORIDE (The Merck Index) 
A. IUPAC-Name         :       Dimethyl {5-[2-(1-methylamino-2nitrovinylamino)    
                                                     ethylthiomethyl] furfuryl}-amine hydrochloride.  
B. Structural formula        :  
C
H3CO
H
N
OH
CH3
CH3
HCl.
 
C. Molecular formula : C13H27NO2, HCl    
D. Molecular weight : 313.86 
E. Physicochemical properties (www.Chemicalbook.com) 
Description                             :    White to off white crystalline solid.  
Solubility                                :      Freely soluble in water and methanol, insoluble  
                                                        (or) slightly soluble in acetone. 
Category                                 :      serotonin-norepinephrine reuptake inhibitor(SNRI)   
                                                        class 
Dose                                         :      75-225 mg/day (divided in 2-4 doses)  
5. DRUG AND EXCIPIENTS PROFILE 
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F. Pharmacology (www.About CNSforum.com/venlafaxine)              
 
                Figure 5.1: The mechanism of action of specific 5-HT and noradrenaline       
                                    re-uptake inhibitors 
Venlafaxine is a bicyclic antidepressant, and is usually categorized as a 
serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a 
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Depression is 
associated with reduced levels of the monoamines in the brain, such as 5-HT. The 
selective 5-HT and noradrenaline re-uptake inhibitors (SNRIs) are thought to restore 
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the levels of 5-HT and noradrenaline in the synaptic cleft by binding at their re-uptake 
transporters preventing the re-uptake and subsequent degradation of 5-HT and 
noradrenaline. This re-uptake blockade leads to the accumulation of monoamines in 
the synaptic cleft and the concentration returns to within the normal range. This action 
of SNRIs is though to contribute to the alleviation of the symptoms of depression. In 
the presence of the SNRIs, small amounts of 5-HT and noradrenaline continue to be 
degraded in the synaptic cleft. 
G. Pharmacokinetics (goodman and gilman, 2006) 
                    Absorption   :   Venlafaxine is well absorbed and extensively metabolized 
in the liver. O-desmethylvenlafaxine (ODV) is the only major active metabolite. 
 Volume of distribution   :    7.5±3.7 L/kg 
     Partition coefficient    :    octanol/water- 0.43 
       Oral bioavailability   :    10-45% 
  Plasma half life  :     5hrs. 
 Plasma protein binding   :     27% 
H. Indications (Tripathy K.D., 2008) 
 In endogeneous (major) depression. 
 Obsessive-compulsive and phobic states 
 Anxiety disorder 
 Neuropathic pain 
 Attention deficit-hyperactive disorder in children 
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 Enuresis 
 Migrain 
 Pruritus. 
I. Adverse Effect (www.drugbank.ca) 
            Venlafaxine hydrochloride is generally well tolerated, with a low incidence of 
adverse effects. The most common side effects of venlafaxine are nausea, 
somnolence, headache, dry mouth, sweating, hypotension, nervousness and abnormal 
ejaculation, dizziness, insomnia, sedation and constipation. At high doses, there may 
be an increase in blood pressure.  
J. Drug Interaction  
 Venlafaxine should not be used with MAOIs and at least 14 days should elapse 
between stopping an MAOI and starting treatment with venlafaxine. Although the 
synergistic effects may not be as bad as with other antidepressants, it is still not 
recommended to take venlafaxine with alcohol. Venlafaxine may lower the seizure 
threshold, and co administration with other drugs that lower the seizure threshold such 
as bupropion and tramadol should be done with caution and at low doses. Although 
cimetidine inhibits the hepatic metabolism of venlafaxine, it has no effect on the 
active metabolite of venlafaxine, o-desmethylvenlafaxine 
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 K. Dosage Forms  ( http://en.wikipedia.org/wiki/Venlafaxine)                                                                                
 Tablets            : 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg and 225mg. 
 Tablet             : ER-   37.5 mg, 75 mg, and 150 mg and 225mg. 
 Capsules ER : 7.5 mg (gray/peach), 75 mg (peach), and 150 mg (brownish 
red).    
L. Contraindications 
                         Venlafaxine is not recommended in patient with hypersensitive,   
Glaucoma, Pregnant women,   Heart disease and hypertension.  It should never be used 
with a monoamine oxidase inhibitor (MAOI), as it can cause potentially fatal 
serotonin syndrome. Caution should also be used in those with a seizure disorder. 
5.2. EXCIPIENTS PROFILE 
5.2.1. Chitosan100cps  (Raymond C Rowe., et al., 2003) 
Chitosan is one of naturally available product and is a very versatile compound. 
Although studies on chitin and chitosan were initiated in the early nineteenth century, 
most of the reports available today on its medical and pharmaceutical applications 
have been obtained only during the last couple of decades. Despite the considerable 
research carried out on chitosan over recent decades, new registered products have 
failed to reach the market  
 Sources and synthesis of chitosan 
It is derived from a material called chitin, which is an amino polysaccharide, 
extracted from the powdered shells of crustaceans like shrimps and crabs. Chitosan is 
prepared by partial deacetylation of chitin. To prepare chitin, crab and shrimp shells 
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are demineralised in dilute, HCl deproteinated in dilute NaoH, and then decolourised 
in potassium permanganate. The chitin is then deacetylated to become chitosan by 
boiling it in a concentrated NaoH solution. Biochemical grade/purified chitosan is 
prepared by repeating the deacetylation process. Pharmaceutical grade chitosan is 
deacetylated between 90 and 95% and food grade between 75 and 80%. 
 Structural nature 
 Chemical Formula   (C6H11O4N)n . 
 Structural Formula      
                             
 Bio physicochemical Properties Of Chitosan 
 Colour: Yellowish white in colour. 
 Physical Appearance:  Occurs as flakes. 
 Viscosity: 100cps 
 Degree Of Deacetylation:   > 85% 
 Molecular Weight: <10,000. 
 Heavy Metals: Maximum 40 ppm. 
 Loss On Drying: Maximum 10 percent, determined on 1 gram by drying in an 
oven at 100-105°C. 
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 Storage: A t a temperature of 2-8°C, protected from moisture and light. 
 Solubility: Sparingly soluble in water and practically insoluble in ethanol. 
Freely Soluble in dilute acids. pH: 4.0 – 6.0. pKa: 6.2-7.0. Chitosan salts are 
soluble in water; the solubility depends on the degree of deacetylation and the 
pH of the solution.  
 Pharmaceutical Requirements of chitosan   
           particle size <30 μm, density between 1.35 and 1.40 g/cm3, pH 6.5-7.5, in 
soluble in water, and partially soluble in acids. The chemical and biological properties 
of chitosan are summarized in below  Chemical and biological properties of chitosan. 
 Chemical and biological properties of chitosan 
Chemical Properties of Chitosan 
 Cationic polyamine 
 High charge density at pH <6.5 
 Forms gels with polyanions 
 Viscosity, high to low 
 Chelates certain transitional metals 
 Amiable to chemical modification 
 Reactive amino/hydroxyl groups 
 High molecular weight, linear Polyelectrolyte 
 Adheres to negatively charged surfaces 
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Biological Properties of Chitosan 
  Biocompatible 
 Natural polymer 
 Biodegradable to normal body 
 Constituents 
 Safe and non-toxic 
 Used as Haemostatic, bacteriostatic and fungi static 
 Spermicidal 
 Anti-cancerogen 
 Anti-cholesteremic 
 Safety 
Presently  used is approved as an food additives in most of the countries is 
being considered and approved as safe polymer in humans. The oral toxicity of 
chitosan has been reported to 1g/kg weight. 
 Pharmaceutical applications 
 Colon targeted drug delivery 
                                Chitosan is a promising polymer for colon drug delivery since it 
can be biodegraded by the colonic bacterial flora and it has mucoadhesive character. 
In vitro release study revealed no release of the drug in gastric pH for 3 hrs and after 
the lag-time, a continuous release for 8– 12 h was observed in the basic pH. 
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 Mucosal delivery 
                             Nowadays, mucosal surfaces such as nasal, per oral and pulmonary 
are receiving a great deal of attention as alternative routes of systemic administration. 
Chitosan has mucoadhesive properties and therefore, it seems particularly useful to 
formulate the bioadhesive Dosage forms for mucosal administration (ocular, nasal, 
buccal, gastro-enteric and vaginal-uterine therapy). Nasal mucosa has high 
permeability and easy access of drug to the absorption site.  
 Cancer therapy 
Gadopentetic acid-loaded CS nanoparticles have been prepared for gadolinium 
neutron-capture therapy. Their releasing properties and ability for long term  retention 
of gadopentetic acid in the tumor indicated that these nanoparticles are useful as 
intratumoral inject able devices for gadolinium neutron capture therapy. 
Biopharmaceutical applications 
 Oral drug delivery 
The bioavailability of drugs has been improved by the use of mucoadhesive 
dosage forms. This is because by prolonging the residence time of drug carriers at the 
absorption site, improved absorption of drugs can be achieved. It is acknowledged 
that higher molecular weight chitosan possesses better mucoadhesion as compared to 
lower molecular weight chitosan. Insulin loaded liposome’s coated with chitosan were 
developed to improve the enteric absorption of insulin. The results of the above-
mentioned study indicated that as chitosan concentration increased in the coating, the 
mucoadhesion improved, resulting in an increased absorption of insulin. This muco-
adhesive property makes chitosan an ideal candidate for buccal delivery of drugs. 
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 Ocular drug delivery 
The poor bioavailability of topically applied ophthalmic drugs implies a necessity 
for frequent instillation to achieve therapeutic effect (Paul and Sharma, 2000:9). This 
inconvenience may be overcome by a prolonged release of the drug in the corneal 
area. The use of chitosan based colloidal suspensions during in vivo studies were 
investigated and showed a significant increase in ocular drug bioavailability.  
 Nasal drug delivery 
Effective nasal drug delivery depends on increased absorption of the drug 
through the nasal mucosa without undesired sideeffects. However, a nasal formulation 
with improved absorption of macromolecules is still a challenge because of the short 
retention time in the nasal cavity due to the efficient physiological clearance 
mechanism. Chitosan may be a good option in nasal drug delivery as it binds to the 
nasal mucosal membrane with an increased retention time and is therefore potentially 
a good absorption enhancer for nasal drug delivery. 
 Parenteral drug delivery 
In controlled release technology, biodegradable polymeric carriers offer 
potential advantages for the prolonged release of low molecular weight compounds. 
The susceptibility of chitosan to liposome makes it biodegradable and an ideal drug 
carrier. Molecules such as bovine serum albumin, diphtheria toxoid and 
bisphosphonates have been successfully incorporated into chitosan microspheres.  
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 Gene delivery 
The development of new carrier systems for gene delivery represents an 
enabling technology for treating many genetic disorders. Since, a critical barrier to 
successful gene therapy remains in the formulation of an efficient and safe delivery 
vehicle, non-viral delivery systems have been increasingly proposed as alternatives to 
viral vectors owing to their safety, stability and ability to be produced in large 
quantities. Chitosan not only increases transformation efficiency but also through the 
addition of appropriate ligands 32 to the DNA-chitosan complex, facilitates more 
efficient gene delivery via receptor-mediated endocytosis without cytotoxic effects 
5.2.2. SODIUM ALGINATE  (Raymond C Rowe., et al., 2003) 
 Nonproprietary Names: 
 BP: Sodium alginate,          PhEur: Natrii alginas, USPNF: Sodium alginate 
 Synonyms: 
  Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; sodium 
 polymannuronate. 
 Chemical Name and CAS Registry Number: 
 Sodium alginate [9005-38-3] 
 Empirical Formula :(C
6
H
7
O
6
Na) n 
 Molecular Weight: The block structure and molecular weight of sodium alginate 
samples has been  investigated. 
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  Structural Formula: 
                         
 Functional Category: 
   Stabilizing agent; suspending agent; tablet and capsule disintegrant; 
tablet binder; viscosity-increasing agent. 
 Grades:  
   Various grades of sodium alginate are available yielding aqueous 
solutions of varying viscosities within a range of 20 to 400 centipoises in 1% 
solution at 20
º
C. 
  Applications in Pharmaceutical Formulation or Technology: 
o Sodium alginate for oral and topical pharmaceutical formulations. 
o  In tablet formulations, sodium alginate may be used as both a binder and 
disintegrant, diluents in capsule formulations. Sustained release oral formulations 
are prepared by using, since it can delay the dissolution of a drug from tablets, 
capsules and aqueous suspensions. In topical formulations, sodium alginate is 
mainly used as a thickening and suspending agent in product such as variety of 
pastes, creams, and gels, and as a stabilizing agent for oil-in-water emulsions  
o  Recently, sodium alginate has been used mostly for microencapsulation of 
drugs, in contrast with the more conventional microencapsulation techniques 
which use  organic solvent systems. It has also been used in the formulation of 
nanoparticles. Other NDDS containing sodium alginate include ophthalmic 
solutions that form a gel in situ when administered to the eye. 
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 Description: 
  Sodium alginate occurs naturally as an odorless and tasteless, white to pale   
yellowish-brown colored powder. 
 Typical Properties: 
 Acidity/alkalinity: pH 7.2 for a 1% w/v aqueous solution 
 Solubility:  
        Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water 
mixtures in which the ethanol content is greater than 30%. Also, the pH is less       
than 3. Slowly soluble in water, forming a viscous colloidal solution. 
 Stability and Storage Conditions: 
  Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative humanities and a cool temperature.  
5.2.3. Xanthan Gum (Raymond C Rowe., et al., 2003)                                       
Nonproprietary Names 
BP : Xanthan gum 
PhEur : Xanthani gummi 
USPNF : Xanthan gum 
Synonyms 
      Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan 
NF; Xantural 
Chemical name and CAS registry number 
Xanthan gum [11138-66-2] 
Molecular weight 
Approximately 2000000. 
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Functional category 
Stabilizing agent; suspending agent and viscosity-increasing agent.   
Description 
Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing,   
fine powder. 
Solubility  
           It is practically insoluble in ethanol and ether, soluble in cold or warm water. 
Viscosity (dynamic) 
           1200-1600 m Pas (1200–1600 cP) for a 1% w/v aqueous solution at 25°C. 
Applications in pharmaceutical formulation or technology 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and foods as a suspending and stabilizing agent. It is also used as a 
thickening and emulsifying agent. It is nontoxic, compatible with most other 
pharmaceutical ingredients, and has good stability and viscosity properties over a 
wide pH and temperature range. When xanthan gum is mixed with certain inorganic 
suspending agents, such as magnesium aluminum silicate, or organic gums, 
synergistic rheological effects occur. It is used as for preparation of sustained release 
matrix tablets and also used as thickening agent in shampoo. 
Stability and storage conditions 
Bulk material should be stored in a well closed container in a cool, dry place.
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6. MATERIALS AND EQUIPMENTS 
6.1. RAW MATERIALS 
Table 6.1: List of raw materials with name of the supplier 
S. No. Name of raw Material Name of the Supplier 
1 Venlafaxine Hydrochloride Orchid Pharmaceticals., Chennai 
2 Chitosan 100cps Micro laboratories Pvt. Ltd., Hosur 
3 Sodium alginate Merk Chemicals, Chennai 
4 Xanthan gum Merk Chemicals,Chennai 
5 Dichloromethane Qualigens fine chemicals, Mumbai 
6 Ethanol Qualigens fine chemicals, Mumbai 
7 Span 80 Loba Chemical Pvt. Ltd. Mumbai, 
8 n-Hexane Loba Chemical Pvt. Ltd. Mumbai, 
9 Liquid paraffin Loba Chemical Pvt. Ltd. Mumbai, 
10 Petroleum ether S d fine-chem limited, Mumbai. 
11 
Sodium hydroxide Qualigens fine chemicals, Mumbai 
12 
Ethanol (95%) S d fine-chem limited, Mumbai. 
13 Potassium dihydrogen 
orthophosphate 
Fischer scientific chemicals, Mumbai. 
14 
Acetone Fischer scientific chemicals, Mumbai. 
15 
Hydrochloric acid S d fine-chem limited, Mumbai. 
16 
Dialysis bag Himedia labaratories ,Mumbai. 
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6.2. EQUIPMENTS 
Table 6.2: List of equipments with company name 
S. No. Name of the Equipments Company 
1.  Over head Propeller Agitator REMI 
2.  Electronic Balance Shimadzu BL-220H 
3.  Rotary shaker 
RS-12R, remi equipments 
limited, vasai 
4.  pHmeter LI120 pHmeter, ELICO LTD 
5.  UV Spectrophotometer 
Shimadzu-1700 Pharmaspec UV-
Visible spectrophotometer 
6.  Differential scanning calorimeter Shimadzu  DSC 60, Japan 
7.  FTIR Spectrophotometer Shimadzu S4008 
8.  Scanning Electronic Microscopy JEOL, JSM-6360, Japan 
9.  
USP Tablet Dissolution 
Apparatus Type II 
USP XXIV (Electro Lab, 
Mumbai). 
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7. EXPERIMENTAL WORK 
7.1. PREFORMULATION STUDY 
 Preformulation testing was an investigation of physical and chemical 
properties of a drug substance alone. It is the first step in rational development of 
dosage form. 
7.1.1. Identification of drug  
7.1.1.1. Identification by FTIR spectroscopy (Skoog D.A.,et al.,1996;) 
Venlafaxine Hydrochloride discs were prepared by pressing the Venlafaxine 
Hydrochloride with potassium bromide and the spectra between 4000-1 to 500-1 cm 
was obtained under the operational conditions. The absorption maximums in spectrum 
obtained with the substance being examined correspond in position and relative 
intensity to those in the reference spectrum represented in Table 8.1 and Figure 8.1 
respectively.  
7.1.1.2. Identification by melting point (www.Chemicalbook.com/venlafaxine) 
Melting point of the drug was determined by capillary tube method. 
7.1.2. Physicochemical parameters 
7.1.2.1. Organoleptic properties    
                                     (Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 1996) 
The color, odor and taste of the drug were recorded using descriptive 
terminology. 
7.1.2.2. Solubility study  
It was important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
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response. The solubility of drug was recorded by using various descriptive 
terminology specified in drugs.com. 
7.1.2.3. Loss on drying  
Loss on drying was the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The accurately weighed 1gm of sample was transferred in glass-stoppered, 
shallow weighing bottle and accurately weighed the bottle. The bottle was transferred 
in oven and substance was dried at 105°C for 3 hours. The bottle was removed from 
oven and reweighed; loss on drying was calculated by following equation, 
 
7.1.3. Analytical methods 
7.1.3.1. Determination of λ max (Sundraganapahty., et al., 2011)                                                                                                                   
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on Shimadzu-1700 Pharmaspec UV-Visible spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in 
position and relative intensity to those in the reference spectrum represented in Figure 
8.2 and 8.4.                                                                                                                    
7.1.3.2. Development of standard curve of Venlafaxine Hydrochloride in 0.1N 
HCl: (Nikhil Karani., et al., 2009)                                                                                                                   
Preparation of 0.1N HCl: 0.1N HCl was prepared according to I.P. 1996. 8.5 
ml of HCl was diluted with fresh distilled water to produced 1000 ml. 
Preparation of stock solution of Venlafaxine Hydrochloride in 0.1 N HCl 
Accurately weighed 100 mg of Venlafaxine Hydrochloride was dissolved in little 
quantity of 0.1 N HCl and volume was adjusted to 100 ml with the same to prepared 
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standard solution having concentration of 1000 µg/ ml then further diluted to get the 
concentration  of 100 µg/ml. 
                        Procedure: From the stock solution, aliquots of 1, 2, 3, 4 and 5 ml 
were transferred to 25 ml volumetric flasks and final volume was made to 25 ml with 
0.1N HCl. Absorbance values of these solutions were measured against blank (0.1N 
HCl) at 225 nm using UV-Visible spectrophotometer. The data was given in Table 8.4 
and 8.5; also shown in Figure 8.3 respectively.  
7.1.3.3. Development of standard curve of Venlafaxine Hydrochloride in pH 7.4 
phosphate buffer 
     Preparation of phosphate buffer pH 7.4: pH 7.4 phosphate buffer was prepared 
by according to I.P 1996. Placed a 50 ml of 0.2M potassium di hydrogen phosphate in 
a 200ml volumetric flask. Added the specified volume of 0.2M sodium hydroxide and 
required volume was made up with distilled water. 
Preparation of stock solution: Accurately weighed 100 mg of Venlafaxine 
Hydrochloride was dissolved in little quantity of pH 7.4 phosphate buffer and volume 
was adjusted to 100 ml with the same to prepared standard solution having 
concentration of 1000 µg/ml, then further diluted to get the concentration  of          
100 µg/ml. 
            Procedure:  From the stock solution, aliquots of 1, 2, 3, 4 and 5  ml were 
transferred to 25 ml volumetric flasks and final volume was made up  to 25 ml with 
pH 7.4 phosphate buffer solution. Absorbance values of these solutions were 
measured against blank (pH 7.4 phosphate buffer solution) at 225.5 nm using UV-
VISIBLE spectrophotometer. The data was represented in Table 8.6 and 8.7; also 
shown in Figure 8.5 respectively.    
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7.1.3.4. Determination of Percentage purity of Drug  
                                                                            (Bindhu Madhavi., et al., 2011) 
Accurately weighed 100 mg of Venlafaxine Hydrochloride was dissolved in 
little quantity of pH 7.4 Phosphate buffer and volume was adjusted to 100 ml with the 
same to prepared standard solution having concentration of 1000 µg/ml. From the 
above solution, aliquots of 3 ml were transferred to 25 ml volumetric flasks and final 
volume was made up to 25 ml with pH 7.4. Absorbance values of these solutions were 
measured against blank (pH 7.4) at 225.5 nm using UV-VISIBLE spectrophotometer. 
The percentage purity of drug was calculated by using calibration graph method (least 
square method).  
7.1.4. Determination of drug-polymer compatibility   (Aulton M.E., 2007) 
The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients to be used in the fabricating the product. Each polymer used in the 
formulations was blended with the drug levels that are realistic with respect to the 
final dosage form. Each polymer was thoroughly blended with drug to increase drug- 
polymer molecular contacts to accelerate the reactions if possible. 
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Figure 7.1: Schematic representation of compatibility studies 
7.1.4.1. Fourier transform Infra-Red (FTIR) spectroscopy  (Sunitha., et al., 2010) 
FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum of Venlafaxine Hydrochloride was determined on Fourier transform 
Infrared Spectrophotometer using KBr dispersion method. The base line correction 
was done using dried potassium bromide. Then the spectrum of dried mixture of drug 
and potassium bromide was run followed by drug with various polymers by FTIR 
spectrophotometer. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in the 
reference spectrum represented in Table 8.7 and was shown in Figure 8.6 to 8.9. 
7.1.4.2. Differential scanning calorimetry (DSC)     (Bindhu Madhavi., et al., 2011) 
Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC study was performed on pure drug, drug+ Chitosan, drug+Sodium alginate and 
drug+ Xanthan gum. The study was carried out using a Shimadzu DSC 60, (Japan). 
The 2 mg of sample were heated in a hermetically sealed aluminum pans in the 
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temperature range of 25-300ºc at heating rate of 10ºc /min under nitrogen flow of 
30ml/min. 
7.2. PREPARATION OF MICROSPHERES       (Kumar Darapu B N.,et al., 2011) 
Nine formulations were prepared by using drug and three different polymers 
in the ratios of 1:1, 1:2 and 1:3 respectively shown in Table 7.1. And represented in 
Figure 7.2. The powder blend (drug with polymer) was dissolved at room temperature 
in ethanol and dichloromethane (1:1% v/v) with vigorous agitation to form uniform 
drug-polymer dispersion. This was slowly poured into the dispersion medium 
consisting of heavy liquid paraffin (50ml) containing 0.5% span 80. The system was 
stirred by using over head propeller agitator at speed of 750 rpm for 5 hours, to 
ensured complete evaporation of the solvent. The liquid paraffin was decanted and the 
microspheres were separated by filtration through a whatmann filter paper. The 
microspheres were separated and washed thrice with 180ml of n-Hexane and air dried 
for 24 hours. 
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Table.7.1: Formulation table for sustained release microspheres of Venlafaxine  
                  Hydrochloride 
 
S.
No INGREDIENS 
FORMULATIONS  
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 
Venlafaxine 
Hydrochloride* 1 1 1 1 1 1 
 
1 
 
1 
 
1 
2 Chitosan* 1 2 3 - - - - - - 
3 
Sodium 
Alginate* - - - 1 2 3 
- - - 
4 Xanthan gum* ` - ` - - - 1 2 3 
5 
Heavy Liquid 
Paraffin# 50  50  50  50  50  50  
 
50 
 
50 
 
50 
6 
Dichloromethane
# 5  5  5  5  5  5  
 
5 
 
5 
 
5 
7 Ethanol# 5  5  5  5  5  5  5  5  5  
8 Span 80 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
0.5
% 
9 n-Hexane# 180 180  180  180  180  180  180  180  180  
* All values are in grams.  # All values are in ml 
 (Formulations F1, F2, and F3 – Venlafaxine Hydrochloride + Chitosan 
  Formulations F4, F5, and F6 – Venlafaxine Hydrochloride + Sodiumalginate 
  Formulations F7, F8, and F9 – Venlafaxine Hydrochloride +Xanthan gum) 
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Figure 7.2: Sustained release Microspheres   
7.3. EVALUATION OF MICROSPHERES 
7.3.1. Percentage yield (Venkatesan P et al., 2011; Bindhu Madhavi., et al., 2011 ) 
          The dried microspheres were weighed and percentage yield of the prepared 
microspheres was calculated by using the following formula. 
Percentage yield = (Weight of Microspheres/Weight of Polymer + drug) X 100 
7.3.2. Drug content estimation (Prasant K., et al., 2009)   
            Drug loaded microspheres (100mg) were powdered and suspended in 100ml 
methanolic :  water  (1:99 v/v)  solvent. The resultant dispersion was kept for 20min 
for complete mixing with continuous agitation and filtered through a 0.45µm  
membrane  filter.  The  drug content  was  determined spectrophotometrically  (UV-
1700, Shimadzu  Japan)  at  225.5nm  using  a regression  equation  derived  from  the 
standard graph (r2=0.9954). 
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7.3.3. Entrapment efficiency of the drug (Bindhu Madhavi B ., et al.,2011) 
         The micro beads equivalent to 10mg of Venlafaxine Hydrochloride were 
weighed and dispersed in PBS of pH 7.4. The resulting mixture was agitated on 
mechanical shaker for 24 hours. The solution was then filtered and drug content was 
estimated by UVspectrophotometry. 
                            Encapsulation Efficiency   = (W1/W2) Χ 100 
                                                                 W1 = Actual Weight of Drug in Sample 
                                                                  W2 = Microspheres Sample Weight 
 
7.3.4. Size distribution of microspheres (Kishore Kumar Reddy  k., et al.,2011) 
               Microspheres were separated into different size fractions by sieving for 10 
minutes using a Mechanical shaker (geologists Syndicate pvt Ltd, India) containing 
standard sieves having Apertures of 710, 500, 355, 250, 125, 80, 60, 45, 30 and 20mm 
(Indian Pharmacopoeia 1996). The particle size distribution of the microspheres for 
all the formulations was determined and mean particle size of microspheres was 
calculated by using the following formula. 
            Mean Particle Size = ∑ (W1 X W2) / (W2) 
                                                         W1 = Mean Particle Size of the Fraction 
                             W2 = Weight Fraction 
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7.3.5. Scanning electron microscopy (SEM) (Kishore Kumar Reddy  k., et al.,2011) 
               The samples for the SEM analysis were prepared by sprinkling the 
microspheres on one side of a double adhesive stub. The stub was then coated with 
gold (Fine coat, Ion sputter, JFC-1100). The microspheres were then observed with 
the scanning electron microscope (JEOL, JSM-6360, scanning electron microscope, 
Japan) at 15kv.  The samples include blank microspheres, drug loaded microspheres. 
7.3.6. In Vitro Release Study (Bindhu Madhavi B ., et al.,2011) 
                 In  vitro drug  release  from microspheres was performed using  the  
rotating  basket  method  as  specified  in  USP XXIV (Electro Lab, Mumbai). 
Microspheres equivalent  to  100 mg  of  venlafaxine hydrochloride  was tied  in  a 
Cellophane membrane  and  put in basket, immersed  in  900 ml  of 0.1  N  HCl (pH 
1.2)  dissolution medium and  allowed  to rotated at 100 rpm. Operating temperature 
was maintained at 37o ± 1oC. Sample (5ml) was withdrawn at predetermined time 
hour intervals up to 2hr. same volume was replaced to maintain sink condition. After 
2hr, dissolution medium was changed by 900ml of fresh phosphate buffer of pH 7.4 
and study was continued upto 16th hour. The samples were analyzed by UV-
spectrophotometer at 225.5 nm.  
7.3.7. Kinetic of In vitro drug release (Mohanraj Palanisamy., et al.,2009)        
 Five kinetic models including the zero order (Equation 1), first order 
(Equation 2), Higuchi matrix (Equation 3) and Peppas-Korsmeyer (Equation 4) 
release equations were applied to process the in vitro released data to find the 
equation with the best fit using Microsoft Office Excel 2007. 
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Where R and UR are the released and unreleased percentages, respectively, at 
time (t); k1, k2, k3 and k4 are the rate constants of zero-order, first-order, Higuchi 
matrix, Peppas-Korsmeyer respectively. 
 
Table 7.2: Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
 
7.4. STABILITY STUDY (Manavalan R. and Ramasamy S., 2004) 
In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date of 
Equation 1 
Equation 2 
Equation 3 
Equation 4 
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manufacture and the packaging of the formulation, until its chemical or biological 
activity was not less than a predetermined level of labeled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
 Objective of the study 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled Stability testing of New Drug Substances and Products describes the 
stability test requirements for drug registration application in the European Union, 
Japan and the States of America. 
ICH specifies the length of study and storage conditions 
  Long-Term Testing: 25
0 
C ±2
0 
C at 60% RH ±5% for 12 Months  
  Accelerated Testing: 40
0 
C ±2
0 
C at 75% RH ±5% for 6 Months  
The selected formulation F3 was exposured  up to 3 months of stability studies 
at accelerated condition (40
0 
C ±2
0 
C at 75% RH ± 5%RH) to find out the effect of  
percentage yield, drug content, entrapment efficiency and in vitro drug release.  
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 Procedure 
Stability studies were carried out accelerated for the selected formulation F3. 
The sustained release microspheres were stored at for accelerated temperature in 
closed in a Aluminium foil for 3 months. The samples were withdrawn after periods 
of 1 month, 2 month and 3 month. The samples were analyzed for its percentage 
yield, drug content, entrapment efficiency and in vitro drug release. 
 
 
  
 
   
 
RESULTS  
AND  
DISCUSSION 
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8. RESULTS AND DISCUSSION 
8.1. preformulation parameters 
8.1.1. Identification of drug  
8.1.1.1. Identification by FTIR spectroscopy 
The FTIR spectrum of Venlafaxine Hydrochloride was showed in Figure 8.1 
and the interpretations of IR frequencies were represented in Table 8.1. 
 
Figure 8.1: FTIR spectrum of Venlafaxine Hydrochloride 
 
 Interpretation of FTIR Spectrum 
Major functional groups methoxy, amine and alcohol groups Present in 
Venlafaxine Hydrochloride were showed at 2935 cm-1, 1317.95 cm-1 and         
1153.46 cm-1 respectively. These peaks were identical to functional group of 
Venlafaxine Hydrochloride. Hence, the sample was confirmed as Venlafaxine 
Hydrochloride.  
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Table 8.1: Characteristic frequencies in FTIR spectrum of Venlafaxine Hydrochloride 
 
Wave No.(cm-1) Inference 
3075.55 C-H stretching 
2935.13 R-O-CH3 stretching 
1317.95 NH2 stretching 
1153.46 OH stretching 
1042.09 CH2 stretching 
836.5 C-H bending 
740.31 OH bending 
8.1.1.2. Melting point 
Melting point values of Venlafaxine Hydrochloride sample was found to be in 
range of 215ºC to 216ºC. The reported melting point for Venlafaxine Hydrochloride 
was 215.3ºC. Hence, experimental values were in good agreement with official values. 
8.1.2. Physicochemical parameters of drug 
8.1.2.1. Organoleptic properties 
Colour:  White to pale off white crystalline powder 
Odour:  Odourless  
Nature: Crystalline powder 
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8.1.2.2. Solubility study 
Solubility of Venlafaxine Hydrochloride was shown in Table 8.2. 
Table 8.2: Solubility of Venlafaxine Hydrochloride in various solvents 
 
 
 
 
 
8.1.2.3. Loss on drying  
The percentage loss on drying after 3 hours was represented in Table 8.3. 
Table 8.3: Percentage loss on drying for Venlafaxine Hydrochloride 
 
The sample passes test for loss on drying as per the limit specified 
(N.M.T.1%). 
 
 
 
 
 
 
Name of solvent Solubility 
Distilled water Freely Soluble 
Methanol Freely Soluble 
Acetone Sparingly Soluble 
S. No. Percentage  LOD Average percentage LOD 
1 0.3  
0.533 
 
2 0.6 
3 0.7 
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8.1.3. Analytical methods 
8.1.3.1. Determination of λ max in 0.1N HCl: 
The absorption maximum for Venlafaxine Hydrochloride in 0.1N HCL was 
found to be 225 nm and  absorption maximum was shown in Figure 8.2. 
 
Figure 8.2:  λ max observed for Venlafaxine Hydrochloride in 0.1N HCl 
8.1.3.2. Preparation of standard graph of Venlafaxine Hydrochloride in 0.1N         
HCl: 
Absorbance was obtained in various concentrations of Venlafaxine 
Hydrochloride in 0.1N HCl were given in Table 8.4 and shown in Figure 8.3. The 
graph of absorbance vs. concentration for Venlafaxine Hydrochloride was found to be 
linear in the concentration range of 4-20 μg /ml. The calibration curve parameters 
shown in Table 8.5. So the drug obeys Beer- Lambert’s law in the range of                 
4-20 μg/ml. 
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Table 8.4:   Data of concentration and absorbance for Venlafaxine Hydrochloride in  
 
                    0.1N HCl 
 
S. No Concentration 
(µg/ml) 
Absorbance 
1 0 0.000 
2 4 0.114 
3 8 0.221 
4 12 0.329 
5 16 0.437 
6 20 0.543 
 
 
 
Figure 8.3:  Standard graph of Venlafaxine Hydrochloride in 0.1N HCl 
Table 8.5:  Data for calibration curve Parameters for 0.1 N HCl 
S. No Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m) 0.02708 
3 Intercept (c) 0.003143 
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8.1.3.3. Determination of λ max in pH 7.4 phosphate buffer saline:  
The absorption maximum for Venlafaxine Hydrochloride in pH 7.4 phosphate buffer 
saline was found to be 225 .5nm and absorption maximum was shown in Figure 8.4. 
 
 
Figure 8.4: λ max observed for Venlafaxine Hydrochloride in PBS 
8.1.3.4. Preparation of standard graph of Venlafaxine Hydrochloride in PH 7.4 
phosphate buffer saline: 
Absorbance obtained for various concentrations of Venlafaxine Hydrochloride 
in PH 7.4 phosphate buffer saline were given in Table 8.6 and shown in Figure 8.5. 
The graph of absorbance vs concentration for Venlafaxine Hydrochloride was found 
to be linear in the concentration range of 4–20 μg /ml. The calibration curve 
parameters shown in Table 8.7.So the drug obeys Beer- Lambert’s law in the range of                  
4–20 μg /ml. 
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Table 8.6:  Data of concentration and absorbance for Venlafaxine Hydrochloride in                  
                   phosphate buffer saline 
 
S. No Concentration 
(µg/ml) 
Absorbance 
1 0 0.0000 
2 4 0.113 
3 8 0.229 
4 12 0.340 
5 16 0.461 
6 20 0.571 
 
 
Figure 8.5:  Standard graph of Venlafaxine Hydrochloride in PBS 
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Table 8.7:  Data for calibration curve Parameters for Venlafaxine Hydrochloride in        
 
                   phosphate buffer saline 
 
 
 
 
 
8.1.4.3. Percentage purity of drug 
The percentage purity of drug was calculated by using calibration graph 
method and represented in Table 8.8. 
Table 8.8: Percentage purity of drug 
  
 
 
 
 
 
The reported percentage purity for Venlafaxine Hydrochloride was 98 to 
102%. 
8.1.5. Determination of compatibility for drug with polymer 
8.1.5.1. By FTIR spectroscopy 
The FTIR spectrums of Venlafaxine Hydrochloride with different polymers 
were used in formulation was showed in Figures 8.6 to 8.9. And represented in Table 
8.9. 
S. No Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m) 0.0287 
3 Intercept (c) -0.0016 
S. No. Percentage purity (%) Avg. percentage 
purity (%) 
1 99.75  
101.14 
2 101.49 
3 102.19 
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Figure 8.6: FTIR spectrum of Venlafaxine Hydrochloride 
 
Figure 8.7: FTIR spectrum of Venlafaxine Hydrochloride with Chitosan 
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Figure 8.8: FTIR spectrum of Venlafaxine Hydrochloride with Sodium alginate  
 
 
Figure 8.9: FTIR spectrum of Venlafaxine Hydrochloride with Xanthan gum 
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Table 8.9: Interpretation of FTIR spectrum 
Functional 
groups 
Peaks observed (wave no. (cm-1)) 
Venlafaxine 
hydrochloride 
Venlafaxine 
hydrochloride + 
chitosan 
Venlafaxine 
hydrochloride + 
Sodium alginate 
Venlafaxine 
hydrochloride + 
Xanthan gum 
C-H 
stretching 3075.55 3074.24 3074.78 3074.55 
R-O-CH3 
stretching 2935.13 2935.09 2935.05 2935.03 
NH2 
stretching 1317.95 1318.06 1317.69 1317.75 
OH stretching 1153.46 1153.40 1153.21 1153.04 
CH2 
stretching 1042.09 1042.56 1041.27 1042.05 
C-H bending 836.5 836.68 838.55 836.35 
OH bending 740.31 740.10 740.13 740.19 
 
FTIR spectrums were compared, it could indicate that there was no 
incompatibility between drug and polymer. 
8.1.5.2. By DSC thermal analysis 
The compatibility and interactions between drug and polymer were observed 
using DSC studies; results obtained were showed in Figure 8.10 to 8.13. 
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Figure 8.10: DSC thermogram of Venlafaxine Hydrochloride 
 
Figure 8.11: DSC thermogram of Venlafaxine Hydrochloride with Chitosan 
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Figure 8.12: DSC thermogram of Venlafaxine Hydrochloride with Sodium alginate 
 
Figure 8.13: DSC thermogram of Venlafaxine Hydrochloride with Xanthan gum 
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Table 8.10: Various DSC thermogram parameters 
S. 
No. 
DSC thermogram  Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
Endset 
temperature 
(°C) 
1 Venlafaxine 
Hydrochloride 
209.88 216.23 222.10 
2 Venlafaxine 
Hydrochloride + 
Chitosan 
210.77 215.45 220.65 
3 Venlafaxine 
Hydrochloride + 
Sodium alginate 
211.01 213.31 221.93 
4 Venlafaxine 
Hydrochloride + 
Xanthan gum 
202.81 214.36 221.81 
 
According to Figures 8.10 to 8.13 and Table 8.10, DSC thermogram showed 
that there was no major difference in onset temperature, peak temperature and end set 
temperature when compared with pure drug’s thermogram. No interaction was found 
between drug and polymers.  
8.2. PREPARATION OF MICROSPHERES 
 Nine formulations of sustained release microspheres of Venlafaxine 
Hydrochloride were prepared by solvent evaporation method. Formulations F1, F2 
and F3 were formulated and prepared Venlafaxine HCL with Chitosan polymer in the 
ratio of 1: 1, 1: 2 and 1: 3. Similarly, formulations F4, F5 and F6 were formulated and 
prepared Venlafaxine HCL with Sodium alginate polymer in the ratio of 1:1, 1:2 and 
1:3; and formulations F7, F8 and F9 were formulated and prepared Venlafaxine HCL 
with Xanthan gum polymer in the ratio of 1: 1, 1: 2 and 1: 3.All the formulations (F1 
to F9) of prepared microspheres were taken for further evaluation studies. 
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8.3. EVALUATION OF MICROSPHERES 
 8.3.1. Percentage Yield, Drug Content and Entrapment Efficiency 
The percentage yield, Drug Content and Entrapment Efficiency of Sustained 
release microspheres were found to increased as the polymer ratio was increased. The 
maximum yield of microspheres was 87.16% in Chitosan polymer, 80.48% in Sodium 
alginate polymer and 83.48% in Xanthan gum. Better yield of microspheres was 
obtained from Chitosan. Drug content and Entrapment efficiency was high in 
Chitosan containing formulations when compared to Sodium alginate and Xanthan 
gum formulations. All the formulations were Percentage Yield, Drug content and 
Entrapment efficiency data was showed in Table 8.11 and showed in Figure 8.14. 
Table 8.11: Percentage yield, Drug content and Percentage Entrapment efficiency 
S. No. FORMULATIONS % YIELD % DRUG CONTENT 
% 
ENTRAPMENT 
1 F1 81.01 43.83 76.41 
2 F2 84.60 57.49 84.77 
3 F3 87.16 69.26 92.09 
4 F4 73.14 43.31 67.35 
5 F5 78.20 49.40 78.50 
6 F6 80.48 53.29 81.11 
7 F7 75.26 39.82 72.75 
8 F8 78.35 52.36 74.8 
9 F9 83.48 62.64 82.33 
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Figure 8.14: Percentage Yield, Drug Content and Entrapment Efficiency 
8.3.2. Particle size analysis 
 Particle size of prepared microspheres was determined by optical microscopy 
method and the average particle sizes of all batches of microspheres were represented 
in Table. 8.12. 
 All the batches of microspheres were prepared by keeping the drug amount 
and solvent volume constant. The particle sizes of the sustained release microspheres 
were found to be in the range of 32.72 µm – 62.57 µm. The results were represented 
graphically in Figure 8.15. 
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Table 8.12: Percentage Mean Particles size 
S. No. FORMULATIONS MEAN PARTICLE SIZE (µm) 
1 F1 43.10 
2 F2 49.25 
3 F3 62.57 
4 F4 35.19 
5 F5 37.05 
6 F6 44.91 
7 F7 32.72 
8 F8 39.78 
9 F9 41.16 
 
Figure 8.15: Percentage Mean Particles size 
8.3.3. Scanning Electron Microscopy Analysis (Surface morphology) 
 Surface morphology and shape characteristics of microspheres were evaluated 
by means of scanning electron microscopy. The SEM photographs of the 
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microspheres revealed that the microspheres were spherical with rough, hollow 
surface and slightly aggregated were showed in Figure 8.16 and 8.17. 
 
 
 
 
 
Figure 8.16: Scanning electron microphotograph of formulation F3 at lower            
                      magnification 
 
 
 
 
 
 
 
 
Figure 8.17: Scanning electron microphotograph of formulation F3 at higher   
 
                      Magnification 
 
8.3.4. In Vitro Dissolution studies 
In-vitro drug released profiles of Venlafaxine Hydrochloride microspheres 
were performed in each formulation up to 2 hours in 0.1N HCl followed by phosphate 
buffer (pH 7.4) up to 16 hours. It was represented in Table 8.13 and showed in Figure 
8.18 to 8.21.
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Table 8.13: Cumulative percentage in-vitro drug released from the formulations F1-F9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       * All the values expressed as mean ± S.D., n=6                     
 
Time in 
hours 
 
pH 
Medium 
Formulations 
F1 
% 
F2 
% 
F3 
% 
F4 
% 
F5 
% 
F6 
% 
F7 
% 
F8 
% 
F9 
% 
 
1 
 
2 
 
 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
10 
 
12 
 
16 
 
 
 
 
pH 1.2         
(simulated                  
gastric 
fluid) 
 
9.63±1.33 
18.75±0.38 
 
9.07±1.54 
 
16.2±1.39 
 
8.99±0.56 
 
14.92±0.56 
 
12.48±1.04 
 
20.9±1.20 
 
10.98±0.64 
 
19.63±0.84 
 
9.16±1.01 
 
17.28±0.73 
 
12.38±0.83 
 
21.63±1.22 
 
10.98±0.80 
 
19.81±1.18 
 
9.87±1.43 
 
18.36±1.43 
 
 
pH 7.4 
(simulated 
intestinal 
fluid) 
 
26.79±0.65 
 
34.98±1.04 
 
41.28±1.06 
 
49.48±1.21 
 
55.82±0.96 
 
59.43±0.46 
 
68.72±0.87 
 
76.84±1.23 
 
91.74±0.89 
 
 
25.77±1.23 
 
29.61±0.87 
 
38.05±0.72 
 
46.57±1.39 
 
51.33±0.69 
 
56.04±0.62 
 
65.21±0.96 
 
70.41±0.78 
 
86.84±0.79 
 
 
 
22.19±0.79 
 
28.37±1.35 
 
31.27±0.72 
 
37.85±1.18 
 
42.18±1.05 
 
47.33±0.96 
 
55.83±0.95 
 
 64.72±1.13 
 
83.14±1.04 
 
 
 
28.48±0.65 
 
38.49±0.96 
 
48.36±0.79 
 
54.83±1.76 
 
57.74±0.46 
 
61.29±0.78 
 
71.82±1.65 
 
79.09±0.62 
 
96.86±0.70 
 
 
 
27.81±0.78 
 
35.61±1.13 
 
45.25±0.52 
 
50.94±0.69 
 
54.81±2.07 
 
59.17±1.41 
 
66.38±0.62 
 
75.48±0.53 
 
93.28±1.12 
 
 
 
25.93±0.95 
 
31.28±0.95 
 
37.47±1.28 
 
49.29±1.23 
 
53.74±0.56 
 
56.49±0.56 
 
65.38±1.05 
 
74.09±1.13 
 
89.03±0.69 
 
 
 
29.38±2.05 
 
37.85±1.48 
 
48.29±0.56 
 
54.38±1.12 
 
58.29±1.84 
 
62.16±1.31 
 
70.29±0.87 
 
78.27±1.46 
 
97.14±0.95 
 
27.14±1.84 
 
37.28±2.30 
 
46.41±0.61 
 
51.16±0.70 
 
57.32±0.87 
 
60.27±1.15 
 
69.38±1.08 
 
75.93±0.78 
 
95.39±0.79 
 
 
 
24.1±0.95 
 
33.93±1.48 
 
42.18±0.78 
 
48.32±0.78 
 
55.29±0.96 
 
59.69±0.95 
 
67.12±1.05 
 
73.26±1.31 
 
91.97±2.21 
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              Table 8.14: Cumulative percentage in-vitro drug released from formulation F1 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
9.63±1.33 9.63 4.79 0.50 
2 18.75±0.38 18.75 9.49 0.99 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
26.79±0.65 26.79 13.88 1.43 
4 34.98±1.04 34.98 18.02 1.90 
5 41.28±1.06 41.28 21.86 2.28 
6 49.48±1.21 49.48 25.72 2.91 
7 55.82±0.96 55.82 29.60 3.30 
8 59.43±0.46 59.43 33.14 3.57 
10 68.72±0.87 68.72 39.39 4.28 
12 76.84±1.23 76.84 44.93 4.95 
16 91.74±0.89 91.74 54.70 6.44 
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Table 8.15: Cumulative percentage in-vitro drug released from formulation F2 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
9.07±1.54 9.07 4.86 0.50 
2 16.2±1.39 16.2 11.82 1.15 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
25.77±1.23 25.77 16.75 1.02 
4 29.61±0.87 29.61 19.43 1.37 
5 38.05±0.72 38.05 22.26 2.04 
6 46.05±1.39 46.05 25.52 2.68 
7 51.33±0.69 51.33 28.84 3.09 
8 56.04±0.62 56.04 31.97 3.44 
10 65.21±0.96 65.21 37.60 4.14 
12 70.41±0.78 70.41 42.66 4.87 
16 86.84±0.79 86.84 51.80 6.43 
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Table 8.16: Cumulative percentage in-vitro drug released from formulation F3 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
8.99±0.56 8.99 4.44 0.50 
2 14.92±0.56 14.92 7.93 0.86 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
22.19±0.79 22.19 11.24 1.45 
4 28.37±1.35 28.37 14.66 1.91 
5 31.27±0.72 31.27 17.58 2.11 
6 37.85±1.18 37.85 20.18 2.64 
7 42.18±1.05 42.18 22.77 3.07 
8 47.33±0.96 47.33 25.06 3.19 
10 55.83±0.95 55.83 29.95 4.78 
12 64.72±1.13 64.72 35.01 5.35 
16 83.14±1.04 83.14 44.71 7.54 
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Table 8.17: Cumulative percentage in-vitro drug released from formulation F4 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
12.48±1.04 12.48 6.84 0.50 
2 20.9±1.20 20.9 12.38 0.88 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
28.48±0.65 28.48 16.78 1.26 
4 38.49±0.96 38.49 21.18 1.87 
5 48.36±0.79 48.36 26.24 2.53 
6 54.83±1.76 54.83 30.98 2.69 
7 57.74±0.46 57.74 34.77 2.86 
8 61.29±0.78 61.29 37.92 3.04 
10 71.82±1.65 71.82 43.48 3.81 
12 79.09±0.62 79.09 48.72 4.65 
16 96.86±0.70 96.86 58.61 6.33 
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Table 8.18: Cumulative percentage in-vitro drug released from formulation F5 
 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
10.98±0.64 10.98 4.79 0.50 
2 19.63±0.84 19.63 9.98 1.04 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
27.81±0.78 27.81 14.40 1.32 
4 35.61±1.13 35.61 18.50 1.94 
5 45.25±0.52 45.25 22.92 2.47 
6 50.94±0.69 50.94 27.34 2.94 
7 54.81±1.76 54.81 31.29 3.12 
8 57.74±0.46 57.74 34.47 3.17 
10 61.29±0.78 61.29 39.47 3.62 
12 71.82±1.65 71.82 43.94 4.54 
16 93.28±1.12 93.28 53.17 6.65 
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Table 8.19: Cumulative percentage in-vitro drug released from formulation F6 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
9.16±1.01 9.16 4.86 0.50 
2 17.28±0.73 17.28 9.17 0.94 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
25.93±0.95 25.93 13.08 1.40 
4 31.28±0.95 31.28 16.60 1.77 
5 37.47±1.28 37.47 20.28 2.47 
6 49.29±1.23 49.29 24.69 3.23 
7 53.74±1.12 53.74 28.95 3.35 
8 56.49±0.56 56.49 32.42 3.52 
10 65.38±1.05 56.49 38.20 4.10 
12 74.09±1.13 74.09 43.19 4.75 
16 89.03±0.69 89.03 52.16 6.37 
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Table 8.20: Cumulative percentage in-vitro drug released from formulation F7 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
12.38±0.83 12.38 6.98 0.50 
2 21.63±1.22 21.63 12.91 0.91 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
29.38±2.05 29.38 17.48 1.22 
4 37.85±1.48 37.85 22.05 1.90 
5 48.29±0.56 48.29 27.13 2.44 
6 54.38±1.12 54.38 31.83 2.69 
7 58.29±1.84 58.29 35.66 2.81 
8 62.16±1.31 62.16 38.90 3.10 
10 70.29±0.87 70.29 44.16 3.41 
12 78.27±1.46 78.27 49.00 4.60 
16 97.14±0.95 97.14 58.98 6.41 
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Table 8.21: Cumulative percentage in-vitro drug released from formulation F8 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                  
gastric fluid) 
10.98±0.80 10.98 5.92 0.50 
2 19.81±1.18 19.81 11.01 0.92 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
27.14±1.84 27.14 15.29 1.33 
4 37.28±2.30 37.28 19.64 1.93 
5 46.41±0.61 46.41 24.28 2.45 
6 51.16±0.70 51.16 28.66 2.79 
7 57.32±0.87 57.32 32.50 3.04 
8 60.27±1.15 60.27 35.92 3.38 
10 69.38±1.08 69.38 41.88 3.95 
12 75.93±0.78 75.93 46.97 4.55 
16 95.39±0.79 95.39 56.59 6.50 
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Table 8.22: Cumulative percentage in-vitro drug released from formulation F9 
 
* All the values expressed as mean ± S.D., n=6 
 
 
 
 
 
Time 
(hours) 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
1 pH 1.2         
(simulated                 
gastric 
fluid) 
9.8±71.43 9.8 5.29 0.50 
2 18.3±61.42 18.3 9.84 0.92 
3 
pH 7.4 
(simulated 
intestinal 
fluid) 
24.1±0.95 24.1 13.22 1.18 
4 33.93±1.48 33.93 16.52 1.87 
5 42.18±0.78 42.18 20.42 2.51 
6 48.32±0.72 48.32 24.04 2.67 
7 55.29±0.96 55.29 27.69 3.53 
8 59.69±0.95 59.69 31.72 4.04 
10 67.12±1.05 67.12 38.56 4.32 
12 73.26±1.31 73.26 43.84 4.76 
16 91.97±2.21 91.97 53.32 6.61 
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Figure 8.18: Graphical representation of Cumulative % in-vitro drug released in            
                      formulations F1-F3 
 
 
 
 
 
 
 
Figure 8.19:  Graphical representation of Cumulative % in-vitro drug released in            
                       formulations F4-F6 
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Figure 8.20:  Graphical representation of Cumulative % in-vitro drug released in            
                       formulations F7-F9 
 
 
 
 
 
 
 
 
 
 
Figure 8.21:  Graphical representation of Cumulative % in-vitro drug released from           
                       formulations F3, F6 and F9              
 
According to in-vitro drug released profiles of the Venlafaxine microspheres 
formulation F1showed that 91.74±0.89% in 16hrs, formulation F2 showed that 
86.84±0.79% in 16hrs, formulation F3 showed that 83.14±1.04% in 16hrs, 
formulation F4 showed that 96.86±0.70% in 16hrs, formulation F5 showed that 
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93.28±1.12% in 16hrs and formulation F6 showed that 89.03±0.69%, formulation F7 
showed that 97.14±0.95% in 16hrs, formulation F8 showed that 95.39±0.79% in 
16hrs and formulation F9 showed that 91.97±2.21%. Solvent evaporation method 
formulation F3 showed better sustained release (83.14%) at the end of the 16th hour 
as compared to other formulations (F1, F2, F4, F5, F6, F7, F8 and F9).  
 
8.5. Release Kinetics of In-vitro Drug Release  
                The kinetics of in-vitro drug released was determined by applying the drug 
release data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer- Peppas. The results obtained were represented in Table 8.23 and shown 
in Figures 8.22 to 8.30. 
Table 8.23:  Release kinetics of in-vitro drug release 
Formulation 
code 
Zero 
order 
 
R2 
First 
order 
 
R2 
Higugi 
 
R2 
Peppas 
 
Best 
model 
R2 n 
F1 0.9621 0.9501 0.9723 0.9908 0.432 Peppas 
F2 0.9650 0.9705 0.9663 0.9909 0.456 Peppas 
F3 0.9900 0.9471 0.9530 0.9985 0.402 Peppas 
F4 0.9503 0.8439 0.9782 0.9908 0.485 Peppas 
F5 0.9592 0.8811 0.9729 0.9903 0.365 Peppas 
F6 0.9622 0.9307 0.9684 0.9903 0.462 Peppas 
F7 0.9540 0.8611 0.9770 0.9901 0.398 Peppas 
F8 0.9597 0.9162 0.9756 0.9907 0.441 Peppas 
F9 0.9647 0.9609 0.9663 0.9907 0.356 Peppas 
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Figure 8.22:  Best fit model (korsemeyer peppas) of formulation F1 
 
 
 
 
 
 
 
Figure 8.23:  Best fit model (korsemeyer peppas) of formulation F2 
 
 
 
 
 
 
              Figure 8.24:  Best fit model (korsemeyer peppas) of formulation F3 
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Figure 8.25:  Best fit model (korsemeyer peppas) of formulation F4 
 
Figure 8.26:  Best fit model (korsemeyer peppas) of formulation F5 
 
Figure 8.27:  Best fit model (korsemeyer peppas) of formulation F6 
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Figure 8.28:  Best fit model (korsemeyer peppas) of formulation F7 
              
             Figure 8.29:  Best fit model (korsemeyer peppas) of formulation F8 
             
            Figure 8.30:  Best fit model (korsemeyer peppas) of formulation F9 
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From the data and graphical representations, the Venlafaxine Hydrochloride 
microspheres formulations were showed well fitted korsemeyer peppas kinetics and 
formulation F3 was showed best among the formulations were prepared based on 
Percentage Yield, Drug content, Percentage Entrapment and in-vitro drug released 
profiles and also well fitted the korsemeyer peppas kinetics 
Table 8.24: Time of drug released values of t25, t50 and t90 for Venlafaxine  
Hydrochloride in sustained release microspheres for formulations F1 to F9 
 
 
Figure 8.31: Histogram for time of drug released values of t25, t50 and t90 of Sustained      
 
                    release microspheres of Venlafaxine hydrochloride formulations F1 to F9 
Formulations 
Time of percentage drug released (hours) 
25%(t 25) 50%(t 50) 90%( t 90) 
F1 2.8 6.0 15.8 
F2 3.0 7.0 >16 
F3 3.5 9.0 >16 
F4 2.5 5.5 14.0 
F5 2.8 6.0 15.0 
F6 3.0 6.1 >16 
F7 2.5 5.3 14.0 
F8 2.8 5.8 15.0 
F9 3.2 6.5 15.8 
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Figure 8.32: In vitro drug released profile of selected formulations (F3, F6 and F9) 
 The time required to released 25% of drug (t25), time required to released 50% 
of drug (t50) and time required to release 90% of drug (t90). The results of t25, t50 and 
t90 are showed in Table 8.24 and Figure 8.31. According to the time of drug released 
values of t25, t50 and t90 the formulations F3, F6 and F9 were selected as the best 
formulation of Chitosan, Sodium alginate and Xanthan gum polymers respectively. 
The drug released profile of selected formulations was showed in Figure 8.32, it was 
observed that formulation F3 was the sustained drug released profile up to 16 hours as 
compared to formulations F6 and F9. Hence the formulation F3 was selected for 
further stability study. 
8.4. STABILITY STUDIES 
 From the results it was found that formulation F3 was the best formulation 
amongst the 9 formulations. Thus formulation F3 was selected for stability studies. 
Formulation F3 was analyzed for Percentage yield, Drug content, Entrapment 
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Efficiency and in vitro drug released at the end of each month up to three months, 
results are shown in Table 8.25 and Figure 8.33 to 8.36. 
                        Table 8.25: Stability studies of selected formulation F3 
 
 
 
Figure 8.33: comparisons of percentage release profile of before and after stability  
 
                      studies for optimized formulation F3.  
EVALUATION 
PARAMETERS 
Initial 1st Month 2nd Month 3rd Month 
Percentage yield 
% 
87.16 87.10 87.04 86.98 
Drug content % 69.86 69.84 69.81 69.77 
% Entrapment 
efficiency 
92.09 92.05 92.01 91.96 
% drug release 83.14 83.15 83.15 83.19 
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Figure 8.34: comparisons of drug content profile of before and after stability studies  
 
                      for optimized formulation F3.  
 
 
 
Figure 8.35: comparisons of entrapment efficiency profile of before and after stability  
 
                      studies for optimized formulation F3.  
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Figure 8.36: Comparison of drug released profile of before and after stability studies  
                      for formulation F3 
 
No major variation was found between evaluated parameters before and after 
stability studies. The sustained release microspheres were showed satisfactory 
physical stability at 40
0
C ± 20 C at 75 % ± 5% RH.                             
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9. SUMMARY AND CONCLUSION 
 
The goal of any drug delivery system was to provide the therapeutic amount of 
drug to the proper site in the body also to achieve and maintain the desired drug 
concentration in blood. Improving the therapeutic efficacy of existing drugs has been 
tried by different technologies. One of the effective technologies exiting in recent 
years of pharmacy is Microspheres. 
 Sustained release drug delivery system was developed in pharmacy field and 
drug retention for a prolonged time has been achieved. Hence, it was made an 
effective attempt to formulate the Sustained release by used Venlafaxine 
hydrochloride as the model drug. 
 Venlafaxine hydrochloride was the serotonin-norepinephrine reuptake 
inhibitors used for the treatment of depression and anxiety disorders. Venlafaxine 
hydrochloride  possess the mean half life of five hours and bioavailability was found 
to be only 27% and high water solubility Hence, it was chosen as the good candidate 
for the sustained release microspheres in order to improve the bioavailability and 
prolong period of drug released. 
Sustained microspheres of Venlafaxine Hydrochloride were successfully 
prepared by solvent evaporation technique and confirmed that it was a best method 
for preparing microspheres from its higher percentage yield. 
The identification of drug was carried out by FTIR spectroscopy and melting 
point. The physicochemical parameters such as appearance, solubility study and loss 
on drying were performed by suitable methods. The analytical profile of drug was  
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evaluated for determination of absorption maximum, development of standard 
curve and percentage purity of drug.  
Compatibility of drug and polymer mixture was done by performing DSC 
study. It was concluded that there was no interaction between the drug and polymer. 
Sustained release microspheres were obtained by solvent evaporation method for all 
the formulations from F1 to F9. Formulations F1, F2 and F3 were prepared 
Venlafaxine HCL with Chitosan polymer in the ratio of 1: 1, 1: 2 and 1: 3. Similarly, 
formulations F4, F5 and F6 were prepared Venlafaxine HCL with Sodium alginate 
polymer in the ratio of 1:1, 1:2 and 1:3; and formulations F7, F8 and F9 were 
prepared Venlafaxine HCL with Xanthan gum polymer in the ratio of 1: 1, 1: 2 and   
1: 3. All formulations were evaluated for the Percentage yield, Entrapment efficiency, 
Particle size, Scanning electron microscopy, and in vitro drug released profile. 
On comparing the major criteria in evaluation such as percentage yield, drug 
content, entrapment efficiency and In-Vitro drug released profile, the formulation F3 
was selected as the best formulation, as it showed the percentage yield as 87.16%, 
drug content as 69.26% and Entrapment efficiency as 92.09% and showed a good 
sustained release nature in the In-Vitro drug released was nearly 83.14% upto 16 hrs. 
Based on all the above evaluation parameters it was concluded that the formulation F3 
was found to be best formulation among the formulations from F1 to F9. The in-vitro 
drug released data was applied to various kinetic models such as zero order kinetics, 
Higuchi plot, first order kinetics and Peppas plot by predict the                                
drug release kinetics mechanism. The formulation F3 was best fitted with Peppas 
kinetics and it undergoes fickian diffusion mechanism (n≥0.5).
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 Based on the in vitro drug released characteristics, entrapment efficiency and 
t25, t50 and t90 values, the formulation F3 was found to be best formulation. By 
increasing the concentration of polymer, decreased the rate of drug released.  
According to stability study it was found that there was no variation in 
Percentage yield, Entrapment efficiency, and in vitro drug released profile of selected 
formulation F3 at specified period. 
The formulation F3 was concluded best formulation among the formulations 
were prepared. 
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10. FUTURE PROSPECTS 
 
 
 Once the technology is fully accepted, these systems will probably increase 
with new pipeline drugs that need enhancement to their bioavailability. 
 The sustained release can also be formulated for advanced drug delivery other 
than oral administration. 
 In the present work the sustained microspheres were formulated using natural 
polymers such as Chitosan, Sodium alginate and Xanthan gum by solvent 
evaporation method. In this work only physiochemical property, formulation 
and in vitro evaluation of sustained release microspheres of Venlafaxine 
hydrochloride was done. The study requires attention of researcher to develop 
sustained drug delivery systems using other synthetic polymers. Furthermore, 
the study can be extended to evaluate in-vivo performance and also In-vitro-
In-vivo correlation of the microspheres. 
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